

BIOGRAPHICAL SKETCH*Senior/key personnel and other significant contributors**A detailed CV in Greek is found at:*https://www.pharm.auth.gr/sites/default/files/Vizirianakis_Greek-CV.pdf**NAME: IOANNIS S. VIZIRIANAKIS**

RESEARCHER IDs:	ORCHID ID	0000-0003-1459-9774
	Scopus ID	6701758622
	Web of Science ID	AAK-6067-2020

POSITION TITLE: Associate Professor, Molecular Pharmacology and Pharmacogenomics

EDUCATION/TRAINING:

INSTITUTION AND LOCATION	DEGREE	Completion Date	FIELD OF STUDY
School of Pharmacy, Aristotle University of Thessaloniki (AUTH), Greece	BSc	1981	Pharmacy
School of Pharmacy, Aristotle University of Thessaloniki (AUTH), Greece	PhD	1991	Biochemical and Molecular Pharmacology

Personal Statement

I currently serve as an Associate Professor in Molecular Pharmacology and Pharmacogenomics at Aristotle University of Thessaloniki (AUTH), School of Pharmacy. After receiving my degree in Pharmacy (1981) in AUTH, I joined the Department as research assistant (1985-1990), obtained a PhD (1991) in Biochemical Pharmacology and finally was assigned as Lecturer (1993) and then Assistant Professor (2003) in Pharmacology. Upon my sabbatical on 1997-1999 at Tumor Biology lab, University of California at San Francisco (UCSF), I received a research grant award (1998) from the Cancer Coordinating Committee of University of California at UCSF, USA. Moreover, upon my second sabbatical on 2015-2016 I have been as Associate Professor in the Department of Life Sciences, Faculty of Life and Health Sciences, University of Nicosia, Cyprus. Recently from 2020, I have joined as Visiting Faculty the University of Nicosia, Cyprus.

My published research work focuses on cancer molecular biology and therapy, including innovative issues of translational research, pharmacogenomics, and personalized/precision medicine. In particular, the molecular profiling and the pharmacological assessment of agents and systems aiming to:

- the development and delivery of innovative targeted therapeutics
- delineate crucial molecular mechanisms that govern leukemia cell initiation, unrestricted growth, as well as blockade of differentiation and apoptosis for hematopoiesis/erythropoiesis disorders
- the implementation of nanomedicine, pharmacogenomics and personalized/precision medicine concepts in new drug development, drug delivery and the clinical setting
- the development and application of predictive population-based physiologically-based PD/PK (PBPK) models through the use of Simcyp simulation platform for new drug development, delivery, and individualization of dosage regimens.

A. Positions and Honors**Education/Graduation rank**

1981 Graduation rank: 1st in my class; BSc in Pharmacy, AUTH

Academic Positions

1982-1985 Research assistant in Medicine Chemistry, Department of Pharmaceutical Sciences, AUTH
 1986-1993 Research assistant in Pharmacology, Department of Pharmaceutical Sciences, AUTH
 1993-2003 Lecturer in Pharmacology, Department of Pharmaceutical Sciences, AUTH
 1997-1999 Postdoctoral Fellow, Tumor Biology Laboratory, Oral Cancer Research Center, University of California, at San Francisco (UCSF), San Francisco, CA, U.S.A.
 2004-2007 Assistant Professor in Pharmacology, Dept. of Pharmaceutical Sciences, AUTH
 2008- Today Associate Professor in Molecular Pharmacology & Pharmacogenomics, Dept. of Pharmaceutical Sciences, AUTH
 2015-2016 Associate Professor (Sabbatical), Department of Life and Health Sciences, University of Nicosia, Cyprus
 2020- Today Visiting Faculty, Department of Life and Health Sciences, University of Nicosia, Cyprus

Research Experience

1982-1985: Research assistant in Pharmaceutical Chemistry (AUTH)
 1985-1991: Research assistant in Pharmacology (AUTH)
 1991-1993: Postdoctoral fellow in Pharmacology (AUTH)
 1997-1999: Postdoctoral Fellow, UCSF, San Francisco, CA, USA

Sabbatical

1997-1999 Tumor Biology Laboratory, Oral Cancer Research Center, Department of Stomatology, University of California, at San Francisco (UCSF), U.S.A
 2015-2016 Department of Life and Health Sciences, University of Nicosia, Cyprus

Fellowships and Awards

1978 Undergraduate achievement fellowship from the Greek Government (IKY)
 1979 Undergraduate achievement fellowship from the Greek Government (IKY)
 1980 Undergraduate achievement fellowship from the Greek Government (IKY)
 1998 Research Grand Award, University of California, Cancer Coordinating Committee, USA
 2011 Short-listing for the "Simcyp teaching award", Simcyp Academic Awards, Simcyp International Consortium
 2013 2nd Best Poster Award In: "Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells", COST Action CM1106, September 19-20, 2013, Warsaw, Poland.
 2015 Research achievement award, Faculty of Health Sciences, AUTH
 2016 Research Achievement Award, Faculty of Health Sciences, AUTH
 2017 Teaching Achievement Award, Faculty of Health Sciences, AUTH
 2018 Silver medal in the iGEM competition, Boston, USA, for the project GALENE (Scientific coordinator), "iGEM Thessaloniki 2018"
 2019 Honorary award, Faculty of Health Sciences, AUTH (Scientific coordinator, of the undergraduate group "iGEM Thessaloniki 2018" (project GALENE; Silver medal, Boston, USA)]
 2019 Research Achievement Award, Faculty of Health Sciences, AUTH
 2019 Teaching Achievement Award, Faculty of Health Sciences, AUTH
 2019 Honorary Award, Aristotle University of Thessaloniki (project GALENE; "iGEM Thessaloniki 2018"]
 2019 Achievement Specific Award (Work recognition to society), Faculty of Health Sciences, AUTH
 2019 Achievement Specific Award (Work impact on science), Faculty of Health Sciences, AUTH
 2019 International Academic Award – "The Most Effective Teaching Application", 2019 Simcyp Academic Awards, Simcyp International Consortium, Sheffield, UK.

- 2019 Research Achievement Award, (Research funding raising), Faculty of Health Sciences, AUTH
- 2019 Gold medal in the iGEM competition, Boston, USA, for the project POSEIDON (Scientific advisor), "iGEM Thessaloniki 2019"
- 2020 Research Achievement Award (Research funding raising), Faculty of Health Sciences, AUTH
- 2020 Research Achievement Award (External evaluator international recognition), Faculty of Health Sciences, AUTH
- 2020 Specific Research Achievement Award (International conference receiving awards), Faculty of Health Sciences, AUTH
- 2020 Honorary award, AUTH, [Scientific advisor of the undergraduate group "iGEM Thessaloniki 2019" (project POSEIDON; Gold medal, Boston, USA)]
- 2021 University of Nicosia (UNIC) Research Recognition Policy Award
- 2021 International Academic Award – "The Most Effective Teaching Application", 2021 Simcyp Academic Awards, Simcyp International Consortium, Sheffield, UK.
- 2021 Award and 1st winner in the category "Idea stage" with the project "METIS" (MiRNA Expression Toehold Investigation System) of «iGEM Thessaloniki 2021" in the competition "Next Stage Challenge" and within the project "Intelligent Cross Border Accelerator for ICT-enabled start-ups (iCBA)" of the Transborder Cooperation EE Program INTERREG" (Coordinator/Principal Investigator)

Editorial Board member (EBM) and reviewer in peer-review journals

- Reviewer in more than 30 international peer-review journals
- Editor/Editorial board member in 8 international peer-review journals [*Advanced Drug Delivery Reviews (Theme Editor); Frontiers in Pharmacology-section Pharmacogenetics and Pharmacogenetics (EBM); Biomedical Reports (EBM); Future Pharmacology (EBM); Journal of Biological Research-Thessaloniki (EBM); Pharmaceuticals (Theme Editor); Cells (EBM); Cells (EBM); World Journal of Pharmacology (EBM)*]

Member in Scientific Societies

- Member in 8 scientific international and national scientific societies

Data submission into DNA data banks

Cloning and characterization of four mouse and human genes Gen/EMBL: Y12431; Y16430; AF072132; AJ300739, as well as four non-coding RNA transcripts (FM992847, FM992848, FM992849, and FM992850)

Member of the organizing/scientific committees in meetings

a) International Scientific meetings

- 2019** Hellenic Bioinformatics 11 Conference: «*Precision medicine, biodiversity & genome biology*». October 11-13, Heraklion, Crete, Greece. (Member of the Organizing Committee)
- 2018** Hellenic Bioinformatics 11 Conference: "*Genome informatics, precision medicine & clinical omics in a world of data economies*". November 15-18, Thessaloniki, Greece. (Member of the Organizing Committee)
- 2017** Hellenic Bioinformatics 10 Conference: "*Bioinformatics Applications in Life Sciences: In Health, Biodiversity and Environment*". September 6-8, 2017, Heraklion, Crete, Greece (Organizing Committee)
- 2016** Hellenic Bioinformatics 09 Conference: "*Bioinformatics as a growth engine for Greece*". November 19-21, 2016, Thessaloniki, Greece. (Organizing Committee)
- 2015** COST Action CM1106 3rd Working Group Meeting. "*Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells*", March 26-27, 2015, Athens
- 2015** 8th International Symposium. "*Computational Methods in Toxicology and Pharmacology Integrating Internet Resources*" (CMTPI-2015), June 21-25, 2015, Chios Island, Greece
- 2013** BBBB International Conference. "*From Drug Discovery and Formulation Strategies to Pharmacokinetics-Pharmacodynamics*", September 26-28, 2013, Athens (BBBB-EUFEPS) (Local Organizing Committee)

b) National scientific meetings

- Organizing/Scientific committee member in **eight (8)** national scientific conferences

Member of drug regulatory bodies–Committee member

2005-2011 Member of the “Pharmacovigilance Committee”, National Organization of Medicines (Greece)

2015- 2017 Member of the AUTH International Graduate Studies Committee

Organization of Continuous Education (CE) Programs

2010 Coordinator; CE program for pharmacists in collaboration with the “US Pharmacist” and “Medscape”

2016 Scientific coordinator for the section “Pharmacogenetics – Pharmacogenomics” of the CE program on “Medical Genetics”, School of Medicine, University of Ioannina, Greece

2021 Coordinator; CE pharmaceutical education program for Pharmacists, Thessaloniki Pharmaceutical Association, Greece

1987 Laboratory of Pharmacology, School of Pharmacy, Aristotle University of Thessaloniki

Co-founding member of scientific societies and network consortia

2016 - Hellenic Bioinformatics Society

2012- Hematopoiesis Initiative Network (HemIN)

2007- CancerNet – Network of Excellence, Research Committee of AUTH

Theme Journal Editor

2012 *Theme issue: “Personalized Nanomedicine”*. (2012). **Vizirianakis IS**, Fatouros D (Eds). *Advanced Drug Delivery Reviews*, 64(13):1359-1544.

Book Editor

2014 **Vizirianakis IS** (Ed). *Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy*; Pan Stanford Publishing: Singapore; 2014 (**1st edition**). ISDN: 978-9814411196.

In Greek

2020 **Vizirianakis IS** (Ed). (In Greek) Translation of “*Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy*”; University Studio Press: Thessaloniki, Greece. 2020. ISBN: 978-960-12-2483-1

2016 **Vizirianakis IS** (Ed). (In Greek) *Clinical Pharmacokinetics: Basic principles of pharmaceutical care in clinical practice*. Stamoulis-Sartinas Publishing; Thessaloniki Greece, 2016 (**3rd edition**). ISDN: 978-618-5161-29-3.

Director/Coordinator in postgraduate curricula

2002-2018 Coordinator of the course “*Drug Interactions*”, Postgraduate program in “*Pharmacology and Therapeutics*”, School of Pharmacy, AUTH, Greece

2011 - 2015 Coordinator in the postgraduate curriculum for “*Pharmacology and Therapeutics*”, School of Pharmacy, AUTH, Greece

2018 - Member of the “Five-member Management Committee”, Postgraduate program “*Industrial Pharmacy*”, School of Pharmacy, AUTH, Greece (https://www.pharm.auth.gr/el/industrial_pharmacy)

2018 - Coordinator in the course “*Regulatory guidelines in drug development and clinical trials*” in the Postgraduate program “*Industrial Pharmacy*”, School of Pharmacy, AUTH, Greece (https://www.pharm.auth.gr/el/industrial_pharmacy)

2020 - Vice Director, Postgraduate program in “*Precision Medicine-Translational Research, and Therapeutics*”, Schools of Medicine and Pharmacy, AUTH, Greece

2020 - Coordinator of the course “*Pharmacogenomics*”, Postgraduate program in “*Precision Medicine-Translational Research, and Therapeutics*”, Schools of Medicine and Pharmacy, AUTH, Greece (<http://precision.med.auth.gr/>)

2020 - Coordinator of the course “*Modern methodology in new drug development*”, Postgraduate program in “*Precision Medicine-Translational Research, and Therapeutics*”, Schools of Medicine and Pharmacy, AUTH, Greece (<http://precision.med.auth.gr/>)

2020 - Member of the “Five-member Management Committee”, Postgraduate program in “*Precision Medicine-Translational Research, and Therapeutics*”, Schools of Medicine and Pharmacy, AUTH, Greece (<http://precision.med.auth.gr/>)

- 2020 - Member of the “Coordinating Specific interschool Committee” in the Postgraduate interdepartmental program in “*Precision Medicine-Translational Research, and Therapeutics*”, Schools of Medicine and Pharmacy, AUTH, Greece (<http://precision.med.auth.gr/>)
- 2021 - Coordinator of the course “*Pharmacogenomics*”, Postgraduate program in “*Personalized Medicine*”, Schools of Medicine and Pharmacy, University of Patras, Greece

Coordinator of postgraduate and/or undergraduate student groups with achievements

- “Sticky Team”, a postgraduate student group, that succeeded as finalist in the international competition of European Space Agency (ESA) (Project: Assessment of microgravity on the adhesion behavior of cancerous cell lines) (https://www.esa.int/Education/13_teams_selected_for_next_stage_of_Fly_Your_Thesis!_2_012)
- “iGEM Thessaloniki 2018”, an undergraduate student group, that received silver medal with the “Project GALENE» -(*A genetic toolbox that enhances system stability by disassociating gene expression from copy number and provides translational control of protein production*)- in the International Genetically Engineered Machine (iGEM) competition (Boston, USA) (<http://2018.igem.org/Team:Thessaloniki>)
- “iGEM Thessaloniki 2019”, an undergraduate student group, that received gold medal with the “Project POSEIDON» -(*A toolkit for the examination of DNA-Protein interactions*)- in the International Genetically Engineered Machine (iGEM) competition (Boston, USA) (<https://2019.igem.org/Team:Thessaloniki>)
- “iGEM Thessaloniki 2021”, an undergraduate student group, that will participate in the International Genetically Engineered Machine (iGEM) competition to be held in Paris, October 2021

Supervisor and/or committee member in MSc and/or PhD theses

- Supervisor in **7 PhD, 18 MSc and 38 diploma theses**
- Supervising and/or examination committee member in **22 PhD and 24 MSc theses**

PI/Collaborator in pharmacogenomics/personalized medicine clinical trials

- 2019 - PI; “Pan-Cardio-Genetics Clot Assessment in Acute Coronary Syndromes (PGCA-ACS). **ClinicalTrials.gov Identifier: NCT03832153**
- 2018 - PI; Quantitative Estimation of Thrombus Burden in Patients with STEMI Using Micro-Computed Tomography (QUEST-STEMI) (QUEST-STEMI). **ClinicalTrials.gov ID: NCT03429608**
- 2017 - PI; Development of a Risk Prediction Algorithm Through the Investigation of Genetic Risk Factors and the Complexity of Coronary Artery Disease to Estimate Future Risk of Cardiovascular Events: Angiographic (SYNTAX Score), Clinical and Pharmacogenetic Analysis. (GESS). **ClinicalTrials.gov Identifier: NCT03150680**
- 2017 - PI; Correlation of Genetic Polymorphisms and Clinical Parameters with the Complexity of Coronary Artery Disease. **ClinicalTrials.gov Identifier: NCT03315234**

Patents

- 2019 Papadopoulou LC, Pappas IS, Miliotou A, Vizirianakis IS. Method for the development of a delivery platform to produce deliverable PTD-IVT-mRNA therapeutics. Hellenic Industrial Property Organisation (OBI) application number 20190100504, filed November 2019.
- 2000 International patent application number PCT/GR2020000059, filed November 11, 2020 (*Publication: International Publication Number: WO 2021/094792 A1 / 20.05.2021*)

Grant Awards and Funding Proposals

A. As Collaborating Researcher:

- 1989-1991 Commission of European Community Research Grant (Biotechnology Action Program) (BAP)
- 1991-1993 Commission of European Community Research Grant (BRIDGE R and D Program on Biotechnology)
- 1994-1997 Greek Secretariat for Science and Technology (ΕΠΕΤ II)
- 1997-1999 Greek Secretariat for Science and Technology (ΕΡΕΑΚ I)

- 1998-2001 Greek Secretariat for Science and Technology (EKBAN)
 1998 Research Grand Award (Postdoctoral Fellowship) UCSF, U.S.A.
 2000-2002 Greek Secretariat for Science and Technology (PENED)
 2002-2004 Greek Secretariat for Science and Technology (Cooperative research grants)
 2002-2005 Greek Secretariat for Science and Technology (EPEAK II)
 2003-2005 Greek Secretariat for Science and Technology (EPEAK II)
 2005-2008 Greek Secretariat for Science and Technology (EPEAK II)

B. As Principal Investigator (PI) and Coordinator:

- 2007-2009 PI; CancerNet – Network of Excellence, Research Committee of AUTH (Co-founding member)
 2012 PI; Hematopoiesis Initiative Network (HemIN) (Co-founding member)
 2009-2021 PI; “*Simcyp* – Population Based Pharmacokinetic Modeling and Simulation” (Academic license agreement) (<https://www.certara.com/the-simcyp-consortium/>)
 2011 PI; “Assessment of ribosomal protein RPS5 and RPL35a functions in MEL cell erythroid differentiation with potential clinical relevance in myelodysplastic syndromes”; Research Committee of AUTH.
 2011 PI; “Clinical assessment of gene expression molecular signatures in patients suffering hematopoiesis disorders”; Genesis Pharma.
 2012-2016 Member of the Management Committee (MC) in the COST Action CM1106 entitled “Chemical approaches to targeting drug resistance in cancer stem cells” (StemChem) grant funded by the EU Framework Programme. (<https://www.cost.eu/actions/CM1106/#tabsName:management-committee>).
 2014-2015 PI; “Microporous inorganic materials (zeolites) for the oral delivery of poorly soluble drugs”. Co-funded by General Secretariat for Research and Technology (GSRT) and the European Union, Program ARISTEIA II.
 2015 PI; “Development of drug delivery formulations for poorly-soluble active substances”. Pharma-oriented project funded by Rontis Pharma.
 2016 PI; “Permeability assessment of solid drug formulations in cell cultures”. Pharma-oriented project funded by Pharmathen Pharma.
 2016-2017 PI; Industry-oriented funded project: “Assessment of molecular signatures of circulating tumor cells in cancer therapy”. Biogenea Pharmaceuticals.
 2017 PI; Exploitation of genetic and clinical data in the therapeutic outcome of heart disease suffering Greek population. Hellenic Cardiological Foundation.
 2017 PI; Risk assessment factors contributing to angina complexity in the Greek population: SYNTAX score, clinical evaluation, and pharmacogenetics analysis. Hellenic Cardiological Society.
 2018-2021: PI/Scientific coordinator; Development of a Risk Prediction Algorithm Through the Investigation of Genetic Risk Factors and the Complexity of Coronary Artery Disease to Estimate Future Risk of Cardiovascular Events: Angiographic (SYNTAX Score), Clinical and Pharmacogenetic Analysis. (GESS). Co-financed by the Hellenic Foundation for Research and Innovation (HFRI) and the European Union, ESPA 2014-2020, Cooperative Funding Program “Research-Technological Development and Innovation”.
 2018-2019: PI/Coordinator; Molecular signatures analysis of three-dimensional cell cultures and circulating tumor cells in the treatment of cancer. Co-funded by the Hellenic Foundation for Research and Innovation (HFRI) and the European Union (European Social Fund-ESF).
 2018-2019: PI/Coordinator; Systems pharmacology analysis of the ribosomal protein expression. Co-funded by General Secretariat for Research and Technology (GSRT) and the Hellenic Foundation for Research and Innovation (HFRI).

Reviewer-evaluator in funding bodies

Grant applications (for several years) from the “Greek Secretary of Research and Technology”, and the “Greek Ministry of Education”; NASA Postdoctoral Program; European Commission H2020-FET Proactive call.

B. Academic teaching experience and course development**Undergraduate teaching/course development**

- 1993- **Pharmacology I & II** (Biochemical, Molecular and Clinical) (3rd year students); Pharmacy **Undergraduate** curriculum course, Aristotle University of Thessaloniki, Greece (16-24 hrs)
Development of lectures as well as tutorials/practical courses-exercises to assess pharmacological response by using in vitro cell culture models, molecular techniques and/or co-evaluating pharmacogenomics data (selective biomarkers, etc)
- 1995 **Instructor in the 6th Erasmus winter school entitled “From Molecules to Brain”**, Aristotle University of Thessaloniki, Thessaloniki, April 3-9, 1995
- 1996- **Clinical Pharmacokinetics** (4th year students); Pharmacy **Undergraduate** curriculum course, Aristotle University of Thessaloniki, Greece (18-36 hrs)
Development of lectures as well as tutorials/practical courses-exercises on population-based Simcyp platform (predictive PB/PD/PK models for drug behaviour as well as drug interaction prediction and assessment profiles in clinical practice)
- 2001-2003 **Introduction to Pharmaceutical Sciences: historical and regulatory issues** (1st year students); Pharmacy **Undergraduate** curriculum course, Aristotle University of Thessaloniki, Greece (2-4 hrs)
- 2002- **Molecular Pharmacology and Pharmacogenetics**; Pharmacy **Postgraduate** curriculum course, Aristotle University of Thessaloniki, Greece (24 hrs)
Development of lectures as well as tutorials/practical courses-exercises
- 2002-2018 **Drug Interactions**; Pharmacy **Postgraduate** curriculum course; Aristotle University of Thessaloniki, Greece (36 hrs)
Development of lectures as well as tutorials/practical courses-exercises
- 2020- **Pharmacogenomics and Personalized Medicine**; **Undergraduate** course of free choice for all the curricula at Aristotle University of Thessaloniki, Greece (36 hrs)
- 2015-2016 **Undergraduate Pharmacy program, Department of Life and Health Sciences, University of Nicosia, Cyprus**: 1) Clinical Pharmacy (100%, 4th year, 36 hrs); 2) Biopharmaceutics and Clinical Pharmacokinetics (100%, 4th year, 75 hrs); 3) Pharmacogenomics and Pharmaceutical Biotechnology (100%, 4th year, 36 hrs); 4) Therapeutics and Clinical Pharmacy (100%, 4th year, 36 hrs); 5) Pharmacoepidemiology and Pharmacovigilance (100%, 4th year, 26 hrs); 6) Toxicology (100%, 4th year, 36 hrs); 7) Therapeutics and Pharmacy Practice (100%, 4th year, 18 hrs); 8) Molecular-Biochemical Pharmacology (50%, 2nd year, 18 hrs); (9) Drug Discovery and Development (50%, 2nd year., 18 hrs)

Postgraduate teaching/course development

- 2002-2018 Postgraduate program in “Pharmacology and Therapeutics”, School of Pharmacy, Aristotle University of Thessaloniki, Greece (54 hrs)
- 2002-2014 Postgraduate program in “Biotechnology and Molecular Diagnostics”, School of Pharmacy, Aristotle University of Thessaloniki, Greece (18 hrs)
- 2014-2015 Postgraduate program at the School of Biology, Aristotle University of Thessaloniki, Greece
- 2015- Postgraduate program in “Biometrical Sciences”, School of Molecular Biology, Democritus University of Thessaloniki, Greece (2 hrs)
- 2017- Postgraduate program in “Toxicology”, School of Biochemistry and Biotechnology, University of Thessaly, Greece (2 hrs)
- 2017 Postgraduate program of Maxillofacial Surgery Specialty Doctors, Papanicolaou hospital, Thessaloniki, Greece (2 hrs)
- 2018- Postgraduate program in “Industrial Pharmacy”, School of Pharmacy, Aristotle University of Thessaloniki, Greece (18 hrs)
- 2018- Postgraduate program in “Clinical and Industrial Pharmacology”, School of Medicine, Aristotle University of Thessaloniki, Greece (4 hrs)
- 2018- Postgraduate program in “Research Methodology in Medicine and Health Sciences”, School of Medicine, Aristotle University of Thessaloniki, Greece (2 hrs)

2020- Postgraduate Program in “Precision Medicine-Translational Research, and Therapeutics”, Schools of Medicine and Pharmacy, Aristotle University of Thessaloniki, Greece (18 hrs)

C. Contributions to Science

I) At a glance (Cumulatively)

- **Research articles in peer-review journals:** Contribution with 103 publications (Scopus).
- **Book Chapters:** Contribution with 15 chapters to international and with 2 chapters in Greek scientific books
- **Publications-Research articles in Greek:** Contribution with 18 research publications in Greek journals
- **Invited speaker:** Contribution to 58 scientific conferences
- **Proceedings of scientific meeting and conferences:** Contribution with 81 oral and/or poster presentations

ANNEX

A. Detailed list of contributions

A1. List of published research articles in peer-review journals

1. Simakov S, Kartsev V, Petrou A, Nicolaou I, Geronikaki A, Ivanov M, Kostić M, Glamočlija J, Soković M, Talea TD, **Vizirianakis IS**. (2021). 4-(Indol-3-yl) thiazole-2-amines and 4-indol-3-yl)thiazole acylamines as novel antimicrobial agents: Synthesis, in silico and in vitro evaluation. *Pharmaceuticals*, In press.
2. Monou PK, Andriotis EG, Bouropoulos N, Panteris E, Akrivou M, **Vizirianakis IS**, Zeeshan A, Fatouros DG. (2021). Engineered mucoadhesive microparticles of formoterol/budesonide for pulmonary administration. *Eur. J. Pharm. Sci.*, 165:105955. doi: 10.1016/j.ejps.2021.105955.
3. **Vizirianakis IS**, Chatzopoulou F, Karagiannidis E, Papazoglou AS, Stalikas N, Georgios Sofidis G, Stefopoulos C, Kyritsis KA, Mittas N, Theodoroula NF, Lampri A, Mezarli E, Chatzidimitriou D, Pappa-Konidari A, Angelis E, Karvounis C, Sianos G. (2021). The GENetic Syntax Score: a genetic risk assessment implementation tool grading the complexity of coronary artery disease. Rationale and design of the GESS study. *BMC Cardiovascular Disorders*, in press.
4. Miliotou AN, Pappas IS, Spyroulias G, Vlachaki E, Tsiftoglou AS, **Vizirianakis IS**, Papadopoulou LC. (2021). Development of a novel PTD-mediated IVT-mRNA delivery platform for potential clinical application as protein therapy approach for metabolic/genetic disorders. *Molecular Therapy-Nucleic Acids*, In press.
5. Giassafaki LN, Siqueira S, Panteris E, Psatha K, Chatzopoulou F, Aivaliotis M, Tzimagiorgis G, Müllertz A, Fatouros DG, **Vizirianakis IS**. (2021). Towards analyzing the potential of exosomes to deliver microRNA therapeutics. *J Cell Physiol*. 236(2):1529-1544. doi: 10.1002/jcp.29991.
6. Papagiannopoulos CI, Theodoroula NF, **Vizirianakis IS**. (2021). miR-16-5p Promotes erythroid maturation of erythroleukemia cells by regulating ribosome biogenesis. *Pharmaceuticals* 14:137. <https://doi.org/10.3390/ph14020137>.
7. Kyritsis KA, Akrivou MG, Giassafaki L-PN, Grigoriadis NG, **Vizirianakis IS**. (2021). Analyzing TCGA data of differentially expressed EMT-linked genes and miRNAs across various malignancies to identify potential biomarkers. *World Academy J Sci.*, 3: 6.
8. Papagiannopoulos CI, Theodoroula NF, Kyritsis KA, Akrivou MG, Kosmidou M, Tsouderou K, Grigoriadis N, **Vizirianakis IS**. (2021). The histone methyltransferase inhibitor A-366 enhances hemoglobin expression in erythroleukemia cells upon co-exposure with chemical inducers in culture. *J Biol Res (Thessalon)*, 28:2. doi.org/10.1186/s40709-020-00132-3.
9. Christoforidou T, Giasafaki D, Andriotis EG, Bouropoulos N, Theodoroula NF, **Vizirianakis IS**, Steriotis T, Charalambopoulou G, Fatouros DG. (2021). Oral drug delivery systems based on ordered mesoporous silica nanoparticles for modulating the release of aprepitant. *Int J Mol Sci*, 22(4), 1896.
10. Xenikakis I, Tsongas K, Tzimtzimis M, Zacharis C, Theodoroula NF, Kalogianni EP, Demiri E, **Vizirianakis IS**, Tzetzis D, Fatouros DG. (2021). Fabrication of hollow microneedles using liquid crystal display (LCD) vat polymerization 3D printing technology for transdermal macromolecular delivery. *Int J Pharmaceut*, 597:120303. doi: 10.1016/j.ijpharm.2021.120303.
11. Kyritsis KA, Ouzounis CA, Angelis L, **Vizirianakis IS**. (2020). Sequence variation, common tissue expression patterns and learning models: A Genome-wide survey of vertebrate ribosomal proteins. *NAR Genomics and Bioinformatics*, 2(4), lqaa088. <https://doi.org/10.1093/nargab/lqaa088>
12. Astras G, Papagiannopoulos CI, Kyritsis KA, Markitani C, **Vizirianakis IS**. (2020). Pharmacogenomic Testing to Guide Personalized Cancer Medicine Decisions in Private Oncology Practice: A Case Study. *Front. Oncol*. 10:521. DOI: 10.3389/fonc.2020.00521
This article in the news:
 - <https://new.oncodna.com/en/company/activity/news-list/pharmacogenomic-testing-to-guide-personalized-cancer-medicine-decisions-in-private-oncology-practice-a-case-study/>
 - <https://www.oncodna.com/en/company/activity/news-list/47-of-cancer-overall-positive-response-to-treatment-thanks-to-oncodeep-combined-tumour-molecular-profiling/>

13. Eleftheriadis GK, Monou PK, Bouropoulos N, Boetker J, Rantanen J, Jacobsen J, **Vizirianakis IS**, Fatouros DG. (2020). Fabrication of mucoadhesive buccal films for local administration of ketoprofen and lidocaine hydrochloride by combining fused deposition modeling and inkjet printing. *J Pharm Sci.*, 2020 Jun 1:S0022-3549(20)30271-9. doi: 10.1016/j.xphs.2020.05.022. Online ahead of print.
 - *This article is denoted as featured article by the journal*
 - *This article was also selected by the Editors to be featured on the journal's website (<http://www.jpharmsci.org/>) for 3 months under the "Free Virtual Issue" tab (Virtual Issue: Most Original and Most Significant Scientific Findings)*
14. Kontogiannidou E, Meikopoulos T, Virgiliou C, Bouropoulos N, Gika H, **Vizirianakis IS**, Mullertz A, Fatouros DG. (2020). Towards the development of Self-Nano-Emulsifying Drug Delivery Systems (SNEDDS) containing trimethyl chitosan for the oral delivery of amphotericin B: In vitro assessment and cytocompatibility studies. *J Drug Deliv Sci Technol*, 56A:101524. doi: [10.1016/j.jddst.2020.101524](https://doi.org/10.1016/j.jddst.2020.101524)
15. Grigoriadis NG, Kyritsis KA, Akrivou MG Giassafaki, L-P N, **Vizirianakis IS**. (2020). A Novel Combined Methodology for Isolation and Detection of Circulating Tumor Cells based on Flow Cytometry and Cellular Filtration Technologies. *Int J Cancer Clin Res*, 7(1):132. DOI: 10.23937/2378-3419/1410132
16. Kontogiannidou E, Meikopoulos T, Gika H, Panteris E, **Vizirianakis IS**, Müllertz A, Fatouros DG. (2020). In Vitro Evaluation of Self-Nano-Emulsifying Drug Delivery Systems (SNEDDS) Containing Room Temperature Ionic Liquids (RTILs) for the Oral Delivery of Amphotericin B. *Pharmaceutics*, 12(8):699. doi: 10.3390/pharmaceutics12080699.
17. Geronikaki A, Kartsev V, Petrou A, Akrivou MG, **Vizirianakis IS**, Chatzopoulou FM, Lichitsky Bd, Sirakanyan S, Kostic M, Smiljkovic M, Soković M, Druzhilovskiy D, Poroikov V. (2020). Antibacterial activity of griseofulvin analogs as example of drug repositioning. *Int J Antimicrobial Agents*, 55(3):105884.
18. Karavasili C, Andreadis DA, Katsamenis OL, Panteris E, Anastasiadou P, Kakazanis Z, Zoumpourlis V, Markopoulou CK, Koutsopoulos S, **Vizirianakis IS**, Fatouros DG. (2019). Synergistic antitumor potency of a self-assembling peptide hydrogel for the local co-delivery of doxorubicin and curcumin in the treatment of head and neck cancer. *Mol Pharm.* 2019 Jun 3;16(6):2326-2341.
19. **Vizirianakis IS**, Miliotou AN, Mystridis GA, Andriotis EG, Andreadis II, Papadopoulou LC, Fatouros DG. (2019). Tackling pharmacological response heterogeneity by PBPK modeling to advance precision medicine productivity of nanotechnology and genomics therapeutics. *Expert Rev. Precision Medicine and Drug Development*, 4(3): 139-151.
20. Semenok D, Medvedev J, Giassafaki LP, Lavdas I, **Vizirianakis IS**, Eleftheriou P, Gavalas A, Petrou A, Geronikaki A. (2019). 4,5-Diaryl 3(2H)Furanones: Anti-Inflammatory Activity and Influence on Cancer Growth. *Molecules*. 2019 May 6;24(9).
21. Vlassi M, Kyritsis KA, **Vizirianakis IS**, Giannakouros T, Aivaliotis M, Nikolakaki E. (2019). Data on the expression of SRPK1a in mammals. *Data Brief*. 2019 Jul 3;25:104210.
22. Kyriakidis K, Charalampidou A, Natsiavas P, **Vizirianakis IS**, Malousi A. (2019). Linking Exome Sequencing Data with Drug Response Aberrations. *Stud Health Technol Inform.* 2019 Aug 21;264:1845-1846.
23. Papagiannopoulos C, Kyritsis K, **Vizirianakis IS**. (2019). Towards the identification of miRNAs targeting the translational machinery as novel cancer therapeutics. *Aristotle Biomedical Journal*, 1(2): 45-51.
24. Petrou A, Eleftheriou P, Geronikaki A, Akrivou MG, **Vizirianakis I.S.** (2019). Novel Thiazolidin-4-ones as Potential Non-nucleoside Inhibitors of HIV-1 Reverse Transcriptase. *Molecules*, 2019 Oct 23;24(21).
25. Chasapi A, Aivaliotis M, Angelis L, Chanalaris A, Iliopoulos I, Kappas I, Karapiperis C, Kyripides NC, Pafilis E, Panteris E, Topalis P, Tsiamis G, **Vizirianakis IS**, Vlassi M, Promponas VJ, Ouzounis CA. (2019). Establishment of computational biology in Greece and Cyprus: Past, present, and future. *PLoS Comput Biol.* 2019 Dec 19;15(12):e1007532.
26. Eleftheriadis GK, Mantelou P, Karavasili C, Chatzopoulou P, Katsantonis D, Irakli M, Mygdalia A, **Vizirianakis IS**, Fatouros DG. (2019). Development and Characterization of a Self-

- Nanoemulsifying Drug Delivery System Comprised of Rice Bran Oil for Poorly Soluble Drugs. *AAPS PharmSciTech.*, 20(2):78.
27. Akrivou MG, Demertzidou VP, Theodoroula NF, Chatzopoulou FM, Kyritsis KA, Grigoriadis N, Zografos AL, **Vizirianakis IS**. (2018). Uncovering the pharmacological response of novel sesquiterpene derivatives that differentially alter gene expression and modulate the cell cycle in cancer cells. *Int. J. Oncol.*, 53(5):2167-2179.
 28. Karavasili C, Panteris E, **Vizirianakis IS**, Koutsopoulos S, Fatouros DG. (2018). Chemotherapeutic Delivery from a Self-Assembling Peptide Nanofiber Hydrogel for the Management of Glioblastoma. *Pharm Res.*, 35(8):166.
 29. Sayed E, Karavasili C, Ruparelia K, Haj-Ahmad R, Charalambopoulou G, Steriotis T, Giasafaki D, Cox P, Singh N, Giassafaki LN, Mpenekou A, Markopoulou CK, **Vizirianakis IS**, Chang MW, Fatouros DG, Ahmad Z. (2018). Electrospayed mesoporous particles for improved aqueous solubility of a poorly water-soluble anticancer agent: in vitro and ex vivo evaluation. *J. Control Release*, 278:142-155.
 30. Sarrou E, Giassafaki LP, Masuero D, Perenzoni D, **Vizirianakis IS**, Irakli M, Chatzopoulou P, Martens S. (2018). Metabolomics assisted fingerprint of *Hypericum perforatum* chemotypes and assessment of their cytotoxic activity. *Food Chem. Toxicol.*, 114:325-333.
 31. Eleftheriadis GK, Akrivou M, Bouropoulos N, Tsibouklis J, **Vizirianakis IS**, Fatouros DG. (2018). Polymer-lipid microparticles for pulmonary delivery. *Langmuir*, 34(11):3438-3448.
 32. Paparidis G, Akrivou M, Tsachouridou V, Shegani A, **Vizirianakis IS**, Pirmettis I, Papadopoulos MS, Papagiannopoulou D. (2018). Synthesis and evaluation of 99mTc/Retricarbonyl complexes of the triphenylphosphonium cation for mitochondrial targeting. *Nuclear Med. Bio.*, 57:34-41.
 33. Smith JR, Olusanya TOB, Owens AJS, Tseligka E, **Vizirianakis IS**, Tsibouklis J. (2017). Formulation and characterisation of spray-dried o-carborane/ poly(vinylpyrrolidone) for boron neutron capture therapy of liver and lung cancer. *JIPBS*, 4: 9-15.
 34. Karavasili C, Amanatiadou EP, Kontogiannidou E, Eleftheriadis GK, Bouropoulos N, Pavlidou E, Kontopoulou I, **Vizirianakis IS**, Fatouros DG. (2017). Comparison of different zeolite framework types as carriers for the oral delivery of the poorly soluble drug indomethacin. *Int. J. Pharmaceut.*, 528:76-87.
 35. Eleftheriadis GK, Filippousi M, Tsachouridou V, Darda M-A, Sygellou L, Kontopoulou I, Bouropoulos N, Steriotis T, Charalambopoulou G, **Vizirianakis IS**, Van Tendeloo G, Fatouros DG. (2016). Evaluation of mesoporous carbon aerogels as carriers of the non-steroidal anti-inflammatory drug ibuprofen. *Int. J. Pharmaceut.*, 515: 262-270.
 36. Filippousi M, Turner S, Leus K, Siafaka PI, Tseligka E, Nanaki SG, Van Der Voort P, **Vizirianakis IS**, Bikiaris DN, Van Tendeloo G. (2016). Zr-based nano metal organic frameworks coated with modified poly(ϵ -caprolactone) as drug carriers. *Int. J. Pharmaceut.*, 509: 208-218.
 37. Makris G, Tseligka ED., Pirmettis I, Papadopoulos MS., **Vizirianakis IS.**, Papagiannopoulou D. (2016). Development and pharmacological evaluation of new bone-targeted 99mTc radiolabeled bisphosphonates. *Mol. Pharmaceut.*, 13: 2301-2317.
 38. Tseligka ED, Rova A, Amanatiadou EP, Calabrese G, Tsibouklis J, Fatouros DG, **Vizirianakis IS**. (2016). Pharmacological development of target-specific delocalized lipophilic cation-functionalized carboranes for cancer therapy. *Pharm Res.*, 33: 1945-1958.
 39. Papanikolaou N, Pavlopoulos GA, Theodosiou T, **Vizirianakis IS**, and Iliopoulos I. (2016). DrugQuest - A text mining workflow for drug association discovery. *BMC Bioinformatics*, 17(Suppl 5):182. DOI: 10.1186/s12859-016-1041-6.
 40. Grigoriadis NG, Grigoriadis IG, Markoula S, Paschopoulos M, Zikopoulos K, Apostolakopoulos PG, **Vizirianakis IS**, Georgiou I. (2016). Pharmacological preconditioning for short-term ex vivo expansion of human umbilical cord blood hematopoietic stem cells by filgrastim. *Am. J. Stem Cells*, 5(1): 29-38.
 41. **Vizirianakis IS**, Mystridis GA, Avgoustakis K, Fatouros DG, and Spanakis M. (2016). Enabling personalized cancer medicine decisions: The challenging pharmacological approach of PBPK models for nanomedicine and pharmacogenomics. *Oncol. Rep.*, 35: 1891-1904. DOI: 10.3892/or.2016.4575.

42. Amanatiadou EP, Papadopoulos GL, Strouboulis, J, and **Vizirianakis IS**. (2015). Evidence for transcriptional regulation of ribosomal protein genes by GATA1 and PU.1 in erythroid cells: implications for ribosomopathies. *PLoS ONE*, 10(10): e0140077. DOI: 10.1371/journal.pone.0140077.
43. Filippousi M, Siafaka PI, Amanatiadou EP, Nanaki SG, Neratzaki M, Bikiaris DN, **Vizirianakis IS**, Van Tendeloo G. Modified chitosan coated mesoporous strontium hydroxyapatite nanorods as drug carriers. *J. Mat. Chem. B*, (2015), DOI:10.1039/c5tb00827a.
44. Karavasili C, Spanakis M, Papagiannopoulou D, **Vizirianakis IS**, Fatouros DG, and Koutsopoulos S. (2015). Bioactive self-assembling lipid-like peptide as permeation enhancers for oral drug delivery. *J. Pharm. Sci.*, 104(7):2304-2311. doi: 10.1002/jps.24484.
45. **Vizirianakis IS**, Papachristou ET, Andreadis P, Zopounidou E, Matragkou CN, and Tsiftoglou AS. (2015). Genetic manipulation of RPS5 gene expression modulates the initiation of commitment of MEL cells to erythroid maturation: Implications in understanding ribosomopathies. *Int. J. Oncol.*, 47: 303-314.
46. Mehta P., Arshad M.S., Justo L., Walsh S., O'Sullivan C.K., Moghimi S.M., Wilson C., **Vizirianakis I.S.**, Avgoustakis K., Fatouros D.G. and Ahmad Z. (2015). New platforms for multi-functional ocular lenses: Engineering double sided functionalized nano coatings. *J. Drug Targeting*, 13:1-6.
47. **Vizirianakis IS**. (2014). Harnessing pharmacological knowledge for personalized medicine and pharmacotyping: Challenges and lessons learned. *World J. Pharmacol.*, 3(4): 110-119.
48. Fatouros DG, Lamprou DA, Urquhart AJ, Yannopoulos SN, **Vizirianakis IS**, Zhang S, Koutsopoulos S. (2014). Lipid-like self-assembling peptide nanovesicles for drug delivery. *ACS Appl. Mater. Interfaces* 11;6(11):8184-9. doi: 10.1021/am501673x. Epub 2014 May 21.
49. Kyrodinou M, Andreadis D, Drougou A, Amanatiadou EP, Angelis L, Barbatis C, Epivatianos A, **Vizirianakis IS**. (2014). Desmoglein-3/ γ -catenin and E-cadherin/ β -catenin differential expression in oral leukoplakia and squamous cell carcinoma. *Clin Oral Investig.*, 18:199-210.
50. Spanakis M., Bouropoulos N., Sygellou L., Ewart S., Moschovi A.M., Siokou A., Niopas I., Kachrimanis K., Nikolakis V., Cox P.A., **Vizirianakis I.S.**, Fatouros D.G. (2014). Controlled release of 5-fluorouracil from microporous zeolites. *Nanomedicine: NBM*, 10:197-205.
51. Spanakis M, **Vizirianakis IS**, Batzias G, Niopas I. (2013). Pharmacokinetic interaction between losartan and *Rhodiola rosea* in rabbits. *Pharmacology*, 91:112-116.
52. Theodoropoulos D, Rova A, Smith JR, Barbu E, Calabrese G, **Vizirianakis IS**, Tsibouklis J, Fatouros DG. (2013). Towards boron neutron capture therapy: the formulation and preliminary in vitro evaluation of liposomal vehicles for the therapeutic delivery of the dequalinium salt of bis-nido-carborane. *Bioorg. Med. Chem. Lett.*, 23:6161-6166.
53. Karavasili C., Amanatiadou E.P., Sygellou L., Giasafaki D.K., Steriotis T.A., Charalambopoulou G.C., **Vizirianakis I.S.**, Fatouros D.G. (2013). Development of new drug delivery systems based on ordered mesoporous carbons: characterisation and cytocompatibility studies. *J. Mater. Chem. B*, 1:3167–3174.
54. **Vizirianakis I.S.** and Fatouros D.G. (2012). Personalized Nanomedicine: Paving the Way to the Practical Clinical Utility of Genomics and Nanotechnology Advancements. *Adv. Drug Deliv. Rev.*, 64:1359-1362.
55. Karagkiozaki V., Vavoulidis E., Karagiannidis P.G., Gioti M., Fatouros D.G., **Vizirianakis I.S.** and Logothetidis S. (2012). Development of a nanoporous and multilayer drug-delivery platform for medical implants. *Int. J. Nanomedicine*, 7:5327-38.
56. Chatzopoulou M., Bonovolias D.I, Nicolaou I., Demopoulos J.V, **Vizirianakis I.S.**, Tsiftoglou S.A. (2012). Bis-pyrrolyl-tetrazolyl derivatives as hybrid polar compounds: a case of lipophilic functional bioisosterism with bis-acetamides. *Eur. J. Med. Chem.*, 50:75-80.
57. Tezias S.S., Tsiftoglou A.S., Amanatiadou E.P. **Vizirianakis I.S.** (2012). Cloning and characterization of polyA- RNA transcripts encoded by activated B1-like retrotransposons in mouse erythroleukemia MEL cells exposed to methylation inhibitors. *BMB Reports*, 45:126-131.
58. **Vizirianakis IS**, Tezias SS, Amanatiadou EP, Tsiftoglou AS. (2012). Possible interaction between B1 retrotransposon-containing sequences and β major globin gene transcriptional activation during MEL cell erythroid differentiation. *Cell Biol. Int.*, 36: 47-55.

59. Theodosiou T., **Vizirianakis** I.S., Angelis L., Tsaftaris A., Darzentas N. (2011). MeSHy: mining unanticipated PubMed information using frequencies of occurrences and concurrences of MeSH terms. *J. Biomed. Inform.*, 44:919-926.
60. **Vizirianakis** I.S. (2011). Nanomedicine and personalized medicine toward the application of pharmacotyping in clinical practice to improve drug delivery outcomes. *Nanomedicine: NBM*, 7(1):11-17.
61. Termentzi A., Khouri I., Gaslonde T., Prado S., Saint-Joanis B., Bardou F., Amanatiadou E.P., **Vizirianakis** I.S., Kordulakova J., Jackson M., Brosch R., Janin Y.L., Daffé M., Tillequin F., and Michel S. (2010). Synthesis, biological activity, and evaluation of the mode of action of novel antitubercular benzofurobenzopyrans substituted on A ring. *Eur. J. Med. Chem.*, 45(12):5833-5847.
62. **Vizirianakis** I.S., Chatzopoulou M., Bonovolias I.D., Nicolaou I., Demopoulos V.J., and Tsiftoglou A.S. (2010). Toward the development of innovative bi-functional agents to induce differentiation and promote apoptosis in leukemia: Clinical candidates and perspectives. *J. Med. Chem.*, 53(19):6779-810.
63. Magklara E, **Vizirianakis** IS, Macheras P. (2009). Pharmacogenetics in Individualized drug therapy for brain cancer patients. *Pharmakeftiki* 22: 117-123.
64. Matragkou C, Papachristou H, Karetsou Z, Papadopoulos G, Papamarcaki T, **Vizirianakis** IS, Tsiftoglou AS, Choli-Papadopoulou T. (2009). On the Intracellular Trafficking of Mouse S5 Ribosomal Protein from Cytoplasm to Nucleoli. *J Mol Biol.*, 392:1192-1204.
65. Spanakis M, **Vizirianakis** IS, Mironidou-Tzouveleki M, Niopas I. (2009). A validated SIM GC/MS method for the simultaneous determination of dextromethorphan and its metabolites dextrorphan, 3-methoxymorphinan and 3-hydroxymorphinan in biological matrices and its application to in vitro CYP2D6 and CYP3A4 inhibition study. *Biomed Chromatogr.*, 23:1131-1137.
66. Tsiftoglou AS, **Vizirianakis** IS, Strouboulis J. (2009). Erythropoiesis: model systems, molecular regulators, and developmental programs. *IUBMB Life*, 61: 800- 830.
67. Matragkou CN, Papachristou ET, Tezias SS, Tsiftoglou AS, Choli-Papadopoulou T and **Vizirianakis** IS. (2008). The potential role of ribosomal protein S5 on cell cycle arrest and initiation of murine erythroleukemia cell differentiation. *J. Cell. Biochem.* 104:1477-1490.
68. Gougoumas, D.D., **Vizirianakis** I.S., Trivai, I.N. and Tsiftoglou, A.S. (2007). Activation of Prn-p gene and stable transfection of Prn-p cDNA in leukemia MEL and neuroblastoma N2a cells increased production of PrPC but not prevented DNA fragmentation initiated by serum deprivation. *J. Cell. Physiol.*, 211:551-559.
69. **Vizirianakis** I.S. (2007). Clinical translation of genotyping and haplotyping data: Implementation of in vivo pharmacology experience leading drug prescription to pharmacotyping. *Clin. Pharmacokinet.* 46: 807-824.
70. Pappas I.S., Lambris J., **Vizirianakis** I.S., Winter MS and Tsiftoglou A.S. (2005). Mechanisms of action of differentiation inducers: Detection of an inducer-binding protein in murine erythroleukemia cells. *Oncol. Res.*, 15: 21-37.
71. **Vizirianakis** I.S. (2005). Improving pharmacotherapy outcomes by pharmacogenomics: from expectation to reality? *Pharmacogenomics*, 6: 701-711.
72. **Vizirianakis** I.S. and Tsiftoglou A.S. (2005). Blockade of murine erythroleukemia cell differentiation by hypomethylating agents causes accumulation of discrete small poly(A)-RNAs hybridized to 3'-end flanking sequences of β major globin gene. *BBA-MOL. CELL RES.*, 1743: 101-114.
73. **Vizirianakis** I.S. (2004). Challenges in current drug delivery from the potential application of pharmacogenomics and personalized medicine in clinical practice. *Curr. Drug Deliv.*, 1: 73-80.
74. Yeh M-G., Ziober B.L., Liu, B., Lipkina, G., **Vizirianakis** I.S. and Kramer R.H. (2003). The β 1 cytoplasmic domain regulates the laminin-binding specificity of the α 7X1 integrin. *Mol. Biol. Cell* 14: 3507-3518.
75. **Vizirianakis** I.S. (2003). New trends in modern pharmacology: From new innovative therapeutics and sophisticated drug delivery systems to pharmacogenomics and personalized medicine. (Free access at URL: <http://www.onscience.com/ScientificArticle.asp?id=4>).

76. Tsiftoglou A.S., Pappas I.S. and **Vizirianakis I.S.** (2003). Mechanisms involved in the induced differentiation of leukemia cells. *Pharmacol. Therapeut.*, 100: 257- 290.
77. Tsiftoglou A.S., Pappas I.S. and **Vizirianakis I.S.** (2003). The developmental program of murine erythroleukemia cells. *Oncol. Res.*, 13: 339-346.
78. **Vizirianakis**, I.S. (2002). Pharmaceutical education in the wake of genomic technologies in drug development and personalized medicine. *Eur. J. Pharm. Sci.*, 15: 243-250.
79. **Vizirianakis** I.S., Chen Y-Q, Kantak S.S., Tsiftoglou A.S. and Kramer R.H. (2002). Dominant-negative E-cadherin alters adhesion and growth of MCF-7 breast carcinoma cells. *Int. J. Oncol.*, 21: 135-144.
80. **Vizirianakis** I.S., Pappas I.S. and Tsiftoglou A.S. (2002). Differentiation- dependent repression of c-myc, B22, COX II and COX IV genes in murine erythroleukemia (MEL) cells. *Biochem. Pharmacol.*, 63: 1009-1017.
81. Gougoumas D.D., **Vizirianakis** I.S. and Tsiftoglou A.S. (2001). Activation of prion protein (PrP) gene in growth arrested and differentiated mouse and human neoplastic cells. *Exp. Cell Res.*, 264: 408-417.
82. Pappas I.S., **Vizirianakis** I.S. and Tsiftoglou A.S. (2001). Cloning, sequencing, and expression of a cDNA encoding the mouse L35a ribosomal protein during differentiation of murine erythroleukemia (MEL) cells. *Cell Biol. Int.*, 25: 629-634.
83. **Vizirianakis** I.S., Chen Y-Q., Yao C-C., Ziober B.L., Tsiftoglou A.S., and Kramer R.H. (2001). Transfection of MCF-7 carcinoma cells with human integrin $\alpha 7$ cDNA promotes adhesion to laminin. *Arch. Biochem. Biophys.*, 385: 108-116.
84. **Vizirianakis** I.S., Pappas I.S., Gougoumas D.D. and Tsiftoglou A.S. (1999). Expression of ribosomal protein S5 cloned gene during differentiation and apoptosis in murine erythroleukemia (MEL) cells. *Oncol. Res.*, 11(9): 409-419.
85. **Vizirianakis** I.S. and Tsiftoglou A.S., (1996). Induction of murine erythroleukemia cell differentiation is associated with methylation and differential stability of polyA+ RNA transcripts. *Biochim. Biophys. Acta*, 1312: 8-20.
86. **Vizirianakis** I.S. and Tsiftoglou A.S. (1995). N6-methyladenosine inhibits murine erythroleukemia cell maturation by blocking methylation of RNA and memory via conversion to S-(N6-methyl)-adenosylhomocysteine. *Biochem. Pharmacol.*, 50: 1807-1814.
87. **Vizirianakis** I.S., Wong W. and Tsiftoglou A.S. (1992). Analysis of inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation by N6- methyladenosine. *Biochem. Pharmacol.*, 44: 927-936.
88. Mylonas S., Valavanidis A., Dimitropoulos K., Polissiou M., Tsiftoglou A.S., **Vizirianakis** I.S., (1988). Synthesis, Molecular Structure, Determination and Antitumor Activity of Platinum(II) and Palladium(II) Complexes of 2-substituted Benzimidazole. *J. Inorg. Biochem.*, 34: 265-275.

A.2. List of publications as book chapters

1. Kyritsis KA, Angelis E, Ouzounis CA, **Vizirianakis** IS (2019). Understanding specialized ribosomal protein functions and associated ribosomopathies by navigating across sequence, literature, and phenotype information resources. In: *Bioinformatics & Biomedical Data Sciences-Semantics, Analytics and Knowledge*. Kobeissy F, Wang K, Alawieh A, Zaraket FA (Eds). Publisher: Elsevier.
2. **Vizirianakis** IS, Karavasili C., Amanatiadou EP, Fatouros DG. (2016). Advancing the practical clinical utility in personalized medicine: Capabilities and lessons learned for pharmacology and pharmaceuticals. In: *Nanotheranostics for personalized medicine*. Couvreur P. and Mura S. (Eds), pp. 297-323. World Scientific Publishing and Imperial College Press: Singapore & London.
3. **Vizirianakis** I.S. Amanatiadou E.P. and Tezias S.S. (2015). Unveiling transposable elements function to enrich knowledge for human physiology and disease pathogenesis. In: "Genomic Elements in Health, Disease and Evolution: Junk DNA", Felekis K. and Voskarides K. (Eds), pp. 109-127. Springer-Verlag; Berlin-Heidelberg.
4. **Vizirianakis** I.S. (2014). Advancement of pharmacogenomics toward pharmacotyping in drug prescription: Concepts, challenges, and perspectives for personalized medicine. In:

- “Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy”, Vizirianakis I.S (Ed.), pp. 893-852. Pan Stanford Publishing; Singapore.
5. **Vizirianakis** I.S. and Amanatiadou E.P. (2012). Pharmacogenomics and Nanotechnology toward Advancing Personalized Medicine. In: “Nanomedicine and Nanobiotechnology”, Logothetidis S. (Ed.), pp. 115-134. NanoScience and Technology, Springer-Verlag; Berlin-Heidelberg.
 6. **Vizirianakis** I.S., Tezias S.S. and Tsiftoglou, A.S. (2010). The potential role of active methylation cycle into leukemic cell differentiation. In: “Horizons in DNA Research”, Vol. 1, Chesterton J.R. (Ed.), Nova Science Publishers, Inc.; New York, pp. 81-103.
 7. **Vizirianakis** I.S., Spanakis M., Termentzi A., Niopas I. and Kokkalou, E. (2010). Clinical and pharmacogenomic assessment of herb-drug interactions to improve drug delivery and pharmacovigilance. In: “Plants in Traditional and Modern Medicine: Chemistry and Activity”, Kokkalou, E. (Ed.), Transworld Research Network; Kerala, India, pp. 199-234.
 8. **Vizirianakis** I.S. (2007). From defining bioinformatics and pharmacogenomics to developing information-based medicine and pharmacotyping in healthcare. In: “Pharmaceutical Biotechnology Handbook”, Gad S.C (Ed.), John Wiley & Sons, Inc., New York, pp 201-228.
 9. **Vizirianakis** I.S. (2007). The transformation of pharmacogenetics into pharmacogenomics reinforces personalized medicine towards pharmacotyping for improved patient care. In: “New Research on Pharmacogenetics”, Barnes L.P. (Ed.), Nova Science Publishers, Inc.; New York, pp 1-38.
 10. Leontiadou F., Matragou C., Kottakis Ph, Kalpaxis D., **Vizirianakis** I.S., Kouidou S., Tsiftoglou A.S. and Choli-Papadopoulou T. (2004). Genetic engineering of bacterial and eukaryotic ribosomal proteins for investigation on elongation arrest of nascent polypeptides and cell differentiation. In: “Proteome and Protein Analysis” (Eds. R.M. Kamp, J.J. Calvete and Choli-Papadopoulou T.), pp. 251-259, Springer-Verlag, Berlin, Heidelberg.
 11. Tsiftoglou A.S., Pappas, I.S. and **Vizirianakis** I.S. (2001). Pyridine and purine analogs as modulators of murine erythroleukemia (MEL) cell differentiation. In: “Advanced Course on “New Fluoropyrimidines in cancer chemotherapy”, European School of Oncology (ESO), pp. 35-39, Thessaloniki; Greece.
 12. Kramer R.H., Kantak S.S., **Vizirianakis** I.S. and Ziober B.L. (1999). Adhesion molecules in oral cancer progression. In: “Oral Oncology” (Ed. A.K. Varma), vol. VI, pp. 513-518, MacMillan; New York.
 13. Tsiftoglou A.S., **Vizirianakis** I.S. and Pappas I.S., (1996). Regulation of murine erythroleukemia cell differentiation. In: “Regulation of Cell Growth, Differentiation and Genetics in Cancer” (Eds. A.S. Tsiftoglou, A.C. Sartorelli, D.E. Housman and T.M. Dexter), vol. H 99 pp. 295- 307, Springer-Verlag; Berlin- Heidelberg.
 14. **Vizirianakis** I.S. and Tsiftoglou A.S., (1995). Hypermethylation of RNA as part of the differentiation program of murine erythroleukemia (MEL) cells. In: “Challenges of Modern Medicine: Differentiation Therapy” (Ed. S. Waxman), vol. 10, pp. 263-268, Ares-Serono Symposia Publications, Rome.
 15. **Vizirianakis** I.S., Tsiftoglou A.S. and Sklaviadis T. (1994). Developments in slow virus research: Implication of PrP protein involvement in cell growth and differentiation. In: “Transmissible Spongiform Encephalopathies” (Eds. R. Bradley, and B. Marchant), pp. 421-429, Commission of the European Communities, Brussels.
- In Greek**
16. **Βιζιριανάκης** Ι.Σ. (2020). Φαρμακογονιδιωματική και εξατομικευμένη ιατρική: Επιστημονικές εξελίξεις και προοπτικές για τη σύγχρονη φαρμακολογία και θεραπευτική (Νέο κεφάλαιο για την Ελληνική Έκδοση). Στο: «Εγχειρίδιο Εξατομικευμένης Ιατρικής: Εξελίξεις στη Νανοτεχνολογία, στη Χορήγηση Φαρμάκων και στη Θεραπευτική». (Ι.Σ. Βιζιριανάκης, Επιμέλεια πρωτότυπης και Ελληνικής έκδοσης), σελ. 23-53. University Studio Press, Θεσσαλονίκη.
 17. **Βιζιριανάκης** Ι.Σ. (2020). Η πρόοδος της φαρμακογονιδιωματικής προς τη φαρμακοτύπωση κατά τη συνταγογράφηση: Έννοιες, προκλήσεις και προοπτικές για την εξατομικευμένη ιατρική (Μετάφραση του πρωτότυπου κεφαλαίου για την Ελληνική Έκδοση). Στο: «Εγχειρίδιο Εξατομικευμένης Ιατρικής: Εξελίξεις στη Νανοτεχνολογία, στη Χορήγηση Φαρμάκων και στη

Θεραπευτική». (Ι.Σ. Βιζιριανάκης, Επιμέλεια πρωτότυπης και Ελληνικής έκδοσης), σελ. 55-83. University Studio Press, Θεσσαλονίκη.

A-3. Invited Speaker in Scientific Conferences

1. **Vizirianakis, IS.** (2021). (Invited). Achieving the practical clinical utility on the roadmaps of precision medicine to tackle heterogeneity of multifactorial diseases within the healthcare system. 18th International Conference on Nanosciences & Nanotechnologies (NN21), July 6-9, 2021, Thessaloniki, Greece.
2. **Vizirianakis, IS.** (2020). (Invited). Implementation of pharmacogenomics knowledge in the clinical setting to guide precision cancer therapy decisions. 17th International Conference on Nanosciences & Nanotechnologies (NN20), July 7-10, 2020, Thessaloniki, Greece.
3. **Vizirianakis, IS.** (2019). (Invited). Tackling molecular heterogeneity to advance new drug development and therapeutic decisions in precision oncology. 16th International Conference on Nanosciences & Nanotechnologies (NN19), July 2-5, 2019, Thessaloniki, Greece.
4. **Vizirianakis, IS.** (Invited). Implementing clinical trials and harnessing omics knowledge to improve the precision in personalized medicine therapeutics decisions. 15th International Conference on Nanosciences & Nanotechnologies (NN18), July 3-6, 2018, Thessaloniki, Greece.
5. **Vizirianakis, IS.** (Invited). Challenges of personalized/precision medicine in the healthcare environment: Perspectives and opportunities for the Greek society. 3rd E.N.M.F. Congress, Exploring Novel Medical Frontiers, January 26-28, 2018, Thessaloniki, Greece.
6. **Vizirianakis, IS.** (Invited). Enabling personalized cancer medicine through the advancement of nanotherapeutics-focused PBPK models. 14th International Conference on Nanosciences & Nanotechnologies (NN17), July 4-7, 2017, Thessaloniki, Greece.
7. **Vizirianakis, IS.** (Invited). Toward understanding heterogeneity in cancer cell pathophysiology by exploring molecular analysis and pharmacogenomics capabilities. Personalized Cancer Medicine workshop, May 24, 2017, Nicosia, Cyprus.
8. **Vizirianakis, IS** (2016). (Invited). Harnessing pharmacological knowledge for enabling drug delivery in personalized medicine. 2nd International Congress of Controlled Release Society – Greek Local Chapter. June 22-24, 2016, Athens Greece.
9. **Vizirianakis, IS** (2015). (Invited). Toward balancing cellular toxicity and selectivity upon developing innovative bifunctional anticancer therapeutics. 12th International Conference on Nanosciences & Nanotechnologies (NN15), 7-10 July 2015, Thessaloniki, Greece.
10. **Vizirianakis, IS** (2015). (Invited). Toward Personalized Cancer Therapy: Challenges and Lessons Learned for Medicine and Pharmacy. Webinar School of Pharmacy, University of Qatar, March 30, 2015.
11. **Vizirianakis, I.S.** (2014). (Invited). Advancing the practical clinical utility in personalized medicine: Capabilities and lessons learned. Invited contribution to the 11th International Conference on Nanosciences and Nanotechnologies, July 8-11, 2014, Thessaloniki, Greece.
12. **Vizirianakis, I.S.** (2013). (Invited). Personalized nanomedicine crossing the borderlines between pharmacogenomics and nanotechnology to advance cancer therapeutics decisions. Invited contribution to the 5th BBBB International Meeting, September 26-28, 2013, Athens, Greece.
13. **Vizirianakis, I.S.** (2013). (Invited). Personalized nanomedicine: Toward advancing the practical clinical utility of translational medicine decisions. Invited contribution to the meeting “9th International Conference on Nanosciences and Nanotechnologies”, July 9-12, 2013, Thessaloniki, Greece.
14. **Vizirianakis, I.S.** (2012). (Invited). Blockade of Murine Erythroleukemia (MEL) Cell Maturation by Methylation Inhibitors: Lessons Learnt and Challenges for Molecular Pharmacology. Contribution to the 1st Workshop of the COST Action CM1106, July 3-5, 2012, Milano, Italy.
15. **Vizirianakis, I.S.** (2012). (Invited). Uncovering Crucial Molecular Mechanisms of Erythropoiesis to Enable Innovative Therapeutic Approaches for Erythroid Disorders. Invited contribution to the meeting “8th International Conference on Nanosciences and Nanotechnologies”, July 3-7, 2012, Thessaloniki, Greece.

16. **Vizirianakis, I.S.** (2011). (Invited). Toward Advancing the Development of Innovative Molecularly-Targeted Antileukemia Therapeutics: Challenges for Molecular Pharmacology and Nanomedicine. 8th International Conference on Nanosciences and Nanotechnologies, July 12-15, 2011, Thessaloniki, Greece.
17. **Vizirianakis, I.S.** (2010). (Invited). Nanomedicine & Personalized Medicine: The improvement of drug delivery outcomes by pharmacogenomics leading to pharmacotyping in clinical practice. 7th International Conference on Nanosciences and Nanotechnologies, July 11-14, 2010, Ouranoupolis, Halkidiki Greece.
18. **Vizirianakis, I.S.** (2009). (Invited). Epigenetic regulation of erythropoiesis and methylation inhibitors. Mini Symposium on Erythropoiesis and Related Hematological Disorders. June 26, 2009, Thessaloniki.
19. **Vizirianakis, I.S.** (2007). (Invited). The potential role of ribosomal protein S5 in MEL cell differentiation: A transfection/RNAi approach. A workshop on cancer research: Molecular, cellular & therapeutic aspects of cancer, June 1, 2007, Thessaloniki.
20. **Vizirianakis, I.S.** (2007). (Invited). The advent of pharmacogenomics and the new era in drug delivery and pharmacovigilance. 13th Panhellenic Pharmaceutical Congress, May 12-14, 2007, Athens. Eur. J. Drug Metab. Pharmacokin. 32:77.
21. **Vizirianakis I.S.** (2004). (Invited). Pharmacoeconomics and Rational Drug Prescription: The Example of Alzheimer's Disease. Invited contribution to the meeting "Neuroscience Forum", July 10-11, Paphos, Cyprus.

In Greek

22. **Βιζιριανάκης, ΙΣ.** (2020). (Invited). Οι εξελίξεις της φαρμακογονιδιωματικής και συστημικής φαρμακολογίας στη θεραπευτική του καρκίνου. 3^ο Πανελλήνιο Συμμεώνιδιο Συνέδριο Έρευνας του Καρκίνου, 30 Οκτωβρίου - 1 Νοεμβρίου 2020, Θεσσαλονίκη.
23. **Βιζιριανάκης, ΙΣ.** (2019). (Invited). Σύγχρονη φαρμακολογία και θεραπευτική: Καινοτόμες προσεγγίσεις στην έρευνα και κλινική πρακτική. 5ο Πανελλήνιο Συνέδριο Εφαρμοσμένης Φαρμακευτικής. 18-19 Μαΐου, 2019, Θεσσαλονίκη.
24. **Βιζιριανάκης, ΙΣ.** (2018). (Invited). Φαρμακογονιδιωματική και Εξατομικευμένη Ιατρική: Προκλήσεις και προοπτικές στη σύγχρονη θεραπευτική. 1η ημερίδα της Εταιρείας Γενετικής στην Οφθαλμολογία. 20 Οκτωβρίου 2018, Ιωάννινα.
25. **Βιζιριανάκης, ΙΣ.** (2018). (Invited). Αναλύοντας τη φαρμακευτική περίθαλψη και κλινική πρακτική στον Ελληνικό χώρο: Προκλήσεις και προοπτικές. 2ο Φαρμακευτικό Συνέδριο Ανατολικής Μακεδονίας – Θράκη. 19-20 Μαΐου 2018, Ξάνθη.
26. **Βιζιριανάκης, ΙΣ.** (Invited). Ο ρόλος του φαρμακοποιού στη σύγχρονη φαρμακευτική περίθαλψη και εξατομικευμένη ιατρική πρακτική: Προκλήσεις και προοπτικές. 3ο Πανθεσσαλικό Φαρμακευτικό Συνέδριο, 25-26 Νοεμβρίου 2017, Καλαμπάκα.
27. **Βιζιριανάκης, ΙΣ.** (Invited). Ενσωμάτωση Φαρμακογονιδιωματικών Δεδομένων στην Αντιπηκτική Αγωγή. Ημερίδα φοιτητών Φαρμακευτικής ΑΤΡ με τίτλο "Chain Workshops: Γαληνική Φαρμακευτική, Φαρμακογονιδιωματική, Ψυχολογία Ασθενούς", 27 Απριλίου 2017, Θεσσαλονίκη. (Οργάνωση σε συνεργασία του σχετικού workshop με τον κ. Γ. Ραμπίδη παρουσίασης με την μορφή case study για εφαρμογή φαρμακογονιδιωματικών δεδομένων στην κλινική πράξη).
28. **Βιζιριανάκης, ΙΣ.** (Invited). Πρωτοβάθμια φροντίδα υγείας από τα φαρμακεία: Νέες προκλήσεις και προτάσεις. 17ο Pharma Point, 14-15 Οκτωβρίου 2017, Θεσσαλονίκη.
29. **Βιζιριανάκης, ΙΣ.** (Invited). Εξατομικευμένη Θεραπευτική του Καρκίνου: Προκλήσεις για τη Φαρμακολογία και Προοπτικές για την Κλινική Πράξη. 18ο Πανελλήνιο Φαρμακευτικό Συνέδριο, 6-8 Οκτωβρίου, 2017, Αθήνα.
30. **Βιζιριανάκης, ΙΣ.** (Invited). Οι εξελίξεις στη φαρμακολογία και φαρμακογονιδιωματική στην εξατομικευμένη ιατρική του καρκίνου του πνεύμονα. White Ribbon Campaign-Lung Cancer Awareness workshop, 23 Μαΐου 2017, Λευκωσία, Κύπρος.
31. **Βιζιριανάκης, Ι.Σ.** (2016). (Invited). Εξατομικευμένη θεραπεία και φαρμακογονιδιωματική: Προοπτικές και προκλήσεις. Περιφερειακό Ιατρικό Συνέδριο με Διεθνή Συμμετοχή - Exploring Novel Medical Frontiers 2016 (ENMF 2016), 9-10 Απριλίου 2016, Θεσσαλονίκη.

32. **Βιζιριανάκης, Ι.Σ.** (2015). (Invited). Ενίσχυση της ακρίβειας στη θεραπευτική διαμέσου της εξατομικευμένης ιατρικής: Προκλήσεις και προοπτικές για το φαρμακευτικό επάγγελμα. 7ο Παγκύπριο Φαρμακευτικό Συνέδριο, Λευκωσία, Κύπρος, 8-10 Μαΐου, 2015.
33. **Βιζιριανάκης, Ι.Σ.** (2015). (Invited). Εξατομικευμένη ιατρική και συνταγογράφηση φαρμάκων: Προκλήσεις & προοπτικές για το φαρμακευτικό επάγγελμα. 1ο Πανελλήνιο Συνέδριο Εφαρμοσμένης Φαρμακευτικής, ΦΣΘ, Θεσσαλονίκη, April 25- 26, 2015.
34. **Βιζιριανάκης, Ι.Σ.** (2014). (Invited). Εξατομικευμένη χορήγηση φαρμάκων στη σύγχρονη θεραπευτική: Προκλήσεις και προοπτικές για το φαρμακευτικό επάγγελμα. Πρόγραμμα συνεχούς φαρμακευτικής επιμόρφωσης του Φαρμακευτικού Συλλόγου Θεσσαλονίκης. 22 Σεπτεμβρίου, 2014, Θεσσαλονίκη.
35. **Βιζιριανάκης, Ι.Σ.** (2014). (Invited). Σύγχρονη Φαρμακολογική Έρευνα και Εξατομικευμένη Θεραπεία του Καρκίνου: Από την Εκπαιδευτική Διαδικασία στην Κλινική Πράξη. 2ο Συνέδριο Φαρμακευτικών Επιστημών, 9-11 Οκτωβρίου, 2014, Πάτρα.
36. **Βιζιριανάκης, Ι.Σ.** (2011). (Invited). Φαρμακογονιδιωματική και εξατομικευμένη θεραπεία. [Εισήγηση στην στρογγυλή τράπεζα «Εξατομικευμένη φαρμακευτική αγωγή»] 37ο Ετήσιο Πανελλήνιο Ιατρικό συνέδριο. 17-21 Μαΐου 2011, Αθήνα.
37. **Βιζιριανάκης, Ι.Σ.** (2011). (Invited). Φαρμακολογία, Φαρμακογονιδιωματική και εξατομικευση των δοσολογικών σχημάτων στην κλινική πράξη. 1η πανελλήνια Συνάντηση Μεταπτυχιακών Φοιτητών στις φαρμακευτικές Επιστήμες. 8-9 Απριλίου 2011, Αθήνα.
38. **Βιζιριανάκης, Ι.Σ.** (2010). (Invited). Αναγκαιότητα και προοπτικές οργάνωσης πιστοποιημένων προγραμμάτων συνεχούς φαρμακευτικής εκπαίδευσης στην Ελλάδα: Το παράδειγμα του Φαρμακευτικού Συλλόγου Ροδόπης. 9ο Φαρμακευτικό Συνέδριο Μακεδονίας-Θράκης, 7-9 Μαΐου, Σέρρες.
39. **Βιζιριανάκης, Ι.Σ.** (2010). (Invited). Φαρμακογονιδιωματική και εξατομικευση των δοσολογικών σχημάτων στη φαρμακευτική αγωγή. Ημερίδα «Φαρμακογονιδιωματική και εξατομικευμένη θεραπεία», 15 Απριλίου 2010, Θεσσαλονίκη.
40. **Βιζιριανάκης, Ι.Σ.** (2008). (Invited). Φαρμακογονιδιωματική: Καινοτομία στη φαρμακευτική αγωγή. Επιστημονική ημερίδα του Φαρμακευτικού Συλλόγου Καβάλας με θέμα: «Καινοτόμα φάρμακα: Πρόκληση για το φαρμακευτικό επάγγελμα». 1 Ιουνίου 2008, Καβάλα.
41. **Βιζιριανάκης, Ι.Σ.** (2008). (Invited). Σύστημα ρενίνης-αγγειοτενσίνης-αλδοστερόνης: Φαρμακογονιδιωματική ανάλυση του ρόλου του στο καρδιαγγειακό σύστημα. 4ο Ετήσιο Συνέδριο Αθηροσκλήρωσης, 21-23 Φεβρουαρίου 2008, Θεσσαλονίκη.
42. **Βιζιριανάκης, Ι.Σ.** (2007). (Invited). Ασφάλεια και αποτελεσματικότητα των αντιλιπιδαιμικών φαρμάκων: Φαρμακοεπαγρύπνηση και κλινική πράξη. 3ο Ετήσιο Συνέδριο Αθηροσκλήρωσης, 15-17 Μαρτίου 2007, Θεσσαλονίκη.
43. **Βιζιριανάκης, Ι.Σ.** (2007). (Invited). Ασφάλεια και αποτελεσματικότητα στη φαρμακευτική αγωγή: Σύγχρονες θεωρήσεις. Επιστημονική ημερίδα του Φαρμακευτικού Συλλόγου Ροδόπης, 18 Μαΐου 2007, Κομοτηνή.
44. **Βιζιριανάκης, Ι.Σ.** (2006). (Invited). Η φαρμακογονιδιωματική προσέγγιση για τη βελτίωση της αποτελεσματικότητας και ασφάλειας των φαρμάκων στη σύγχρονη θεραπευτική. 9η Επιστημονική Ημερίδα, 9 Απριλίου 2006, Λευκωσία, Κύπρος.
45. **Βιζιριανάκης, Ι.Σ.** (2006). (Invited). Φαρμακογονιδιωματική και εξατομικευση της φαρμακευτικής αγωγής. Ομιλία στα πλαίσια του κύκλου ομιλιών: Κοινωνία & Υγεία, 21 Νοεμβρίου 2006, Εθνικό Ίδρυμα Ερευνών, Αθήνα.
46. **Βιζιριανάκης, Ι.Σ.** (2006). (Invited). Ενίσχυση της ασφάλειας της φαρμακευτικής αγωγής στη σύγχρονη καρδιολογία. 2ο Ετήσιο Συνέδριο Αθηροσκλήρωσης, 23-25 Φεβρουαρίου 2006, Θεσσαλονίκη.
47. **Βιζιριανάκης, Ι.Σ.** (2005). (Invited). Ενίσχυση της ασφάλειας της φαρμακευτικής αγωγής στη σύγχρονη καρδιολογία. 1ο Συνέδριο Κυπριακής Αντιϋπερτασικής Εταιρείας με θέμα: «Η υπέρταση σήμερα», 25-26 Ιουνίου, Πάφος, Κύπρος.
48. **Βιζιριανάκης, Ι.Σ.** (2005). (Invited). Φαρμακευτική αγωγή, φαρμακογονιδιωματική και ο ρόλος του φαρμακοποιού στη σύγχρονη θεραπευτική αγωγή. 6ο Πανελλήνιο Συνέδριο Φοιτητών Φαρμακευτικής με θέμα «Ο ρόλος του νέου φαρμακοποιού στον 21ο αιώνα», 14-17 Απριλίου 2005, Αθήνα.

49. **Βιζιριανάκης, Ι.Σ.** (2005). (Invited). Σύγχρονη φαρμακευτική αγωγή και καρδιαγγειακές παθήσεις. Ομιλία στα πλαίσια της επιστημονικής ημερίδας που διοργάνωσε ο Φαρμακευτικός Σύλλογος Κοζάνης με θέμα: «Στεφανιαία νόσος» 26 Φεβρουαρίου 2005, Κοζάνη.
50. **Βιζιριανάκης, Ι.Σ.** (2004). (Invited). Οι αλληλεπιδράσεις φαρμάκων στην κλινική πράξη και ο ρόλος του φαρμακοποιού στη σύγχρονη φαρμακευτική αγωγή. Ομιλία στα πλαίσια της επιστημονικής ημερίδας που διοργάνωσε ο Φαρμακευτικός Σύλλογος Καβάλας και ο Πανελλήνιος Φαρμακευτικός Σύλλογος στη Θάσος στις 18 Σεπτεμβρίου 2004.
51. **Βιζιριανάκης, Ι.Σ.** (2003). (Invited). Σύγχρονη φαρμακευτική εκπαίδευση και πρόσφατες εξελίξεις στον τομέα έρευνας και ανάπτυξης φαρμάκων. Εισήγηση στα πλαίσια του 4ου Πανελληνίου Συνεδρίου Φοιτητών Φαρμακευτικής με θέμα "Σύγχρονες Διαστάσεις της Φαρμακευτικής", 9-11 Μαΐου, 2003, Θεσσαλονίκη.
52. **Βιζιριανάκης, Ι.Σ.** (2002). (Invited). Η Φαρμακευτική επιστήμη και το επάγγελμα του Φαρμακοποιού στη σημερινή εποχή. Εισήγηση στα πλαίσια της εκδήλωσης επαγγελματικού προσανατολισμού με θέμα "Οι Σπουδές στο Αριστοτέλειο Πανεπιστήμιο Θεσσαλονίκης", 16-18 Δεκεμβρίου, 2002, Θεσσαλονίκη. (Συμμετείχα ως εκπρόσωπος του τμήματος).
53. **Βιζιριανάκης, Ι.Σ.** (2002). (Invited). Ανεπιθύμητες αλληλεπιδράσεις φαρμάκων: Σύγχρονες απόψεις και βασικές αρχές αποφυγής τους στην κλινική πράξη. Ομιλία που δόθηκε στα πλαίσια του φαρμακευτικού συνεδρίου PHARMA Point 2002 που διοργάνωσε ο Φαρμακευτικός Σύλλογος Θεσσαλονίκης, Θεσσαλονίκη 15-17 Νοεμβρίου, 2002.
54. **Βιζιριανάκης, Ι.Σ.** (2002). (Invited). Συνδυασμοί φαρμάκων στην Καρδιολογία: Αλληλεπιδράσεις και Βασικές Αρχές Αποφυγής τους στην Κλινική πράξη. Ομιλία στα πλαίσια συνεδρίου της Καρδιολογικής Εταιρείας της Κύπρου. 13 Απριλίου 2002, Λευκωσία, Κύπρος.
55. **Βιζιριανάκης, Ι.Σ.** (2000). (Invited). Αλληλεπιδράσεις φαρμάκων και τροφίμων. Εισήγηση στα πλαίσια στρογγυλής τράπεζας με θέμα "Αλληλεπιδράσεις φαρμάκων: Συνέργεια και ανταγωνισμός ως αφετηρία θεραπευτικών αλλά και σοβαρών ανεπιθύμητων ενεργειών" στο 18ο Ιατρικό Συνέδριο των Ενόπλων Δυνάμεων, 8-11 Νοεμβρίου, 2000, Θεσσαλονίκη. Τόμος Πρακτικών, σελ. 399-403.
56. **Βιζιριανάκης, Ι.Σ.** (2000). (Invited). Οι εξελίξεις στο χώρο του σχεδιασμού και ανάπτυξης νέων φαρμάκων: Προοπτικές του φαρμακευτικού επαγγέλματος στον 21ο αιώνα. Ομιλία που δόθηκε στα πλαίσια του 5ου Δυτικομακεδονικού Φαρμακευτικού Συνεδρίου, 20-21 Οκτωβρίου, 2000, Χαλκιδική.
57. **Βιζιριανάκης, Ι.Σ.** (1999). (Invited). Αλληλεπιδράσεις φαρμάκων και τροφίμων. Ομιλία που δόθηκε σε ημερίδα που διοργάνωσε ο Φαρμακευτικός Σύλλογος Ημαθίας, 12 Δεκεμβρίου, 1999, Βέροια.
58. **Βιζιριανάκης, Ι.Σ.** (1986). (Invited). Πουρινο- και πυριμιδο- παράγωγα ως φάρμακα για γενετικές αρρώστιες και νεοπλασίες. Ομιλία στα πλαίσια της εκδήλωσης "Φαρμακευτικό Τμήμα, ΑΠΘ: 30 χρόνια φαρμακευτικής εκπαίδευσης και έρευνας", 8-9 Νοεμβρίου 1986, Θεσσαλονίκη.

A-4. List of presentations to Scientific Conferences

1. Astreidis I-S, Paraskevopoulos K, **Vizirianakis IS**, Vaxtsevanos K. (2021). A review of prognostic molecular biomarkers in tongue squamous cell carcinoma. 25th Congress of the European Association for Cranio Maxillo Facial Surgery (EACMFS), (Virtual Event), 14-16 July 2021.
2. Mystridis GA, Batzias G, **Vizirianakis IS**. (2021). Towards the development and clinical validation of physiologically-based pharmacokinetic models for different doxorubicin formulations: Pharmacological correlation and clinical utility. 18th International Conference on Nanosciences & Nanotechnologies (NN21), July 6-9, 2021, Thessaloniki, Greece.
3. Miliotou AN, Pappas IS, Spyroulias GS, Tsiftoglou AS, **Vizirianakis IS**, Papadopoulou LC. (2021). Recruiting mRNA therapeutics and Protein Transduction Domain technology for a metabolic disorder, caused by SCO2 mutations. (Oral Presentation). Hbioinfo Bridge Event 2020-21, Hellenic Bioinformatics Society (virtual), June 2-5, 2021.
4. Papagiannopoulos CI, Kyritsis KA, Theodoroula NF, Kosmidou M, Tsouderou K, **Vizirianakis IS**. (2021). miR-16-5p Promotes Erythroid Maturation of Erythroleukemia Cells by Regulating

- Ribosome Biogenesis. (Oral Presentation). Hbioinfo Bridge Event 2020-21, Hellenic Bioinformatics Society (virtual), June 2-5, 2021.
5. Mystridis GA, Georgios C. Batzias GC, **Vizirianakis** IS. (2021). Towards implementing translational methodologies into nanomedicine and genomics therapeutics through the development and clinical validation of PBPK models for doxorubicin. (Oral Presentation). Hbioinfo Bridge Event 2020-21, Hellenic Bioinformatics Society (virtual), June 2-5, 2021.
 6. Kostoudi S, Papagiannopoulou D, Akrivou M, Katsikini M, Papadimitriou N, **Vizirianakis** I.S., Pinakidou F, Paloura E, Iakovou I, Hadjipavlou-Litina D. (2021). Synthesis and biological evaluation of thiosemicarbazone complexes of Cu(II), [Re(Co)₃] and the radionuclide [^{99m}Tc(Co)₃]. 18th Hellenic Symposium on Medicinal Chemistry, Online Symposium, February 25-27, 2021.
 7. Miliotou AN, Pappas IS, Vlachaki E, Tsiftoglou AS, **Vizirianakis** IS, Papadopoulou LC. (2020). Intracellular delivery of β -globin IVT-mRNA, via the PTD technology, as a novel therapeutic approach for β -thalassemia. 8th International mRNA Health Conference, November 9-10, 2020, Boston, USA.
 8. Papagiannopoulos CI, Theodoroula NF, **Vizirianakis** I.S. (2020). Identification and delivery of microRNAs that target the ribosomal machinery as a therapeutic strategy for hematological malignancies. 17th International Conference on Nanosciences & Nanotechnologies (NN20), July 7-10, 2020, Thessaloniki, Greece.
 9. Papagiannopoulos C, Kyritsis KA, Orfanoudaki G, Stamatakis G, Samiotaki M, Psatha K, Aivaliotis M, **Vizirianakis** I.S. (2019). Proteomic characterization of purified ribosomes in erythropoiesis: Evidence for ribosome heterogeneity. 70th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), Athens, Greece, 28 November - 1 December 2019.
 10. Miliotou AN, Pappas IS, **Vizirianakis** IS, Papadopoulou LC. (2019). A novel intracellular delivery technology for in vitro transcribed (IVT)-mRNAs. 70th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), Athens, Greece, November 28-December 1, 2019.
 11. Miliotou AN, Pappas IS, **Vizirianakis** IS, Papadopoulou LC. (2019). IVT-mRNA conjugated to a protein transduction domain, as a novel gene delivery platform for protein replacement therapy. 7th mRNA Health Conference, at Berlin, Germany, 11-12 November 2019.
 12. Kakafika MG, Lyta AA, Gavriilidis GI, Pappas IS, **Vizirianakis** IS, Tsiftoglou AS, Papadopoulou LC. (2019). Assessment of cellular bioenergetics in human K-562 erythroleukemia cells and HCT116 colorectal cells treated with Imatinib mesylate and/or Dichloroacetate. 70th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), Athens, Greece, 28 November - 1 December 2019.
 13. Theodoroula NF, Akrivou MG, **Vizirianakis** IS. (2018). Pharmacological assessment of small molecule protein methyltransferase inhibitors on erythroid maturation in vitro. 10th Congress of the Hellenic Society for Basic and Clinical Pharmacology, May 25-27, 2018, Ioannina, Greece.
 14. Miliotou AN, Pappas IS, **Vizirianakis** IS, Papadopoulou LC. (2018). Development of in vitro transcribed SCO2 mRNA as novel therapeutic approach in a mitochondrial disorder, due to SCO2 mutations. 69th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), November 23-25, Larissa, Greece.
 15. Akrivou MG, Kyritsis KA, **Vizirianakis** IS. (2018). Differential gene expression profiling of Dsg1 and Dsg3 in HSC-3 and U87 MG cells grown as multicellular aggregates (MCAs) in vitro. 69th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), November 23-25, Larissa, Greece.
 16. Giassafaki L-P, Psatha K, Kyritsis KA, Mullet A, Pavlidou E, Aivaliotis M, Tzimagiorgis G, Fatouros D, **Vizirianakis** IS. (2018). Characterization of exosomes as novel drug delivery systems by multiparametric physicochemical analysis and molecular profiling. 69th Panhellenic Conference of the Hellenic Society for Biochemistry and Molecular Biology (HSBMB), November 23-25, Larissa, Greece.
 17. Kyritsis KA, Angelis L, Ouzounis CA, **Vizirianakis** IS (2018). Differential gene expression patterns of ribosomal proteins across human and mouse tissues. Hellenic Bioinformatics 11

- 2018 Conference, Genome informatics, precision medicine & clinical omics - in a world of data economies, November 15-18, 2018, Thessaloniki, Greece.
18. Papagiannopoulos CI, Kyritsis KA, Felekkis K, **Vizirianakis IS**. (2018). Analyzing the role of miRs in ribosomal proteins gene regulation. Hellenic Bioinformatics 11 - 2018 Conference; Genome informatics, precision medicine & clinical omics - in a world of data economies, November 15-18, 2018, Thessaloniki, Greece.
 19. Giassafaki LP, **Vizirianakis IS**, Passarella D, Nikolaou I. 'Design, synthesis and biological evaluation of a new analogue of Vismodegib', 17th Hellenic Symposium on Medicinal Chemistry (HSMC-17, Designing targeted and safer drugs), Thessaloniki, Greece, June 1-3, 2017.
 20. Kyritsis K, Angelis L, Ouzounis C, **Vizirianakis IS**. (2017) Investigating the specialized roles of ribosomal proteins and associated ribosomopathies by means of literature, protein sequence and phenotype information resources. Hellenic Bioinformatics 10 2017 Conference; Bioinformatics and its applications in Health, Biodiversity and the Environment, 6-9 September 2017, Heraklion.
 21. Paparidis G, Shegani A, Tsachouridou V, Akrivou M, **Vizirianakis IS**, Bouzioti P, Pirmettis I, Papadopoulos M, Papagiannopoulou D. (2017). Development of a new $^{99m}\text{Tc}(\text{CO})_3$ + Chelate of the Triphenylphosphonium Cation as a Potential Tumor Imaging Agent. 22nd International Symposium on Radiopharmaceutical Sciences, 14-19 May 2017, Dresden Germany (Poster P036). *J. Label Comp Radiopharm.* 2017; S186.
 22. Sarrou E, Giassafaki L-P, **Vizirianakis IS**, Masuero D, Chatzopoulou P, Martens S. Identifying the phytochemical and pharmacological profile of different *Hypericum perforatum* accessions', 3rd ICNPU-International Conference on Natural Products Utilization, From Plants to Pharmacy Shelf, Bansko, Bulgaria, 18-21 October 2017.
 23. Paparidis G, Akrivou M, Tsachouridou V, Shegani A, **Vizirianakis IS**, Bouzioti P, Pirmettis I, Papadopoulos MS, Papagiannopoulou D. (2017). Development of a New Technetium-99m Tricarbonyl Chelate of the Triphenylphosphonium Cation as Potential Tumor Imaging Agent. 3rd Panhellenic Pharmacy Schools Conference, 18-19, February 2017, Aristotle University of Thessaloniki, Thessaloniki, Greece.
 24. Amanatiadou E.P., **Vizirianakis IS**. (2016). Assessing the effects of the ectopic expression of ribosomal protein RPL35A in murine erythroleukemia cell differentiation program. 67th Panhellenic Conference of the HSBMB. Ioannina, 25-27 November 2016.
 25. Eleftheriadis GK, Kontogiannidou E, Bouropoulos N, Vouvoudi E, Achilias D, Ritzoulis C, **Vizirianakis IS**, Fatouros DG. (2016). 3D Printed mucoadhesive films for buccal delivery of non-steroidal anti-inflammatory drugs. 2nd International Congress of Controlled Release Society – Greek Local Chapter. June 22-24, 2016, Athens, Greece.
 26. Eleftheriadis GK, Akrivou M, Bouropoulos N, **Vizirianakis IS**, Fatouros DG. (2016). Dry powders of hybrid lipid-polymer microparticles for pulmonary delivery of budesonide. 2nd International Congress of Controlled Release Society – Greek Local Chapter. June 22-24, 2016, Athens, Greece.
 27. Amanatiadou EP, Karavasili C, Eleftheriadis GK, Kontogiannidou E, **Vizirianakis IS**, Fatouros DG. (2016). Pharmacological assessment of hierarchical zeolites BEA, NAX-FAU and ZSM5 for oral delivery of poorly soluble drugs. 2nd International Congress of Controlled Release Society – Greek Local Chapter. June 22-24, 2016, Athens, Greece.
 28. Filippousi M, Turner S, Leus K, Sifaka PI, Tseligka E, Nanaki SG, Van Der Voort P, **Vizirianakis IS**, Bikiaris DN, Van Tendeloo G. (2015). Zr-based nano metal organic frameworks coated with modified poly(ϵ -caprolactone) as drug carriers. NANOBIOAPP2015: Latest Advances on Carbon Nanomaterials for Biomedical Applications, 21-23 September 2015, Barcelona, Spain.
 29. Gkotinakou I.M., Befani C., **Vizirianakis I.S.**, Tsiftoglou A.S., Simos G., Liakos P. (2014). Effect of hypoxia and HIFs on K562 human erythroleukemia cell differentiation. 65th Congress of the Hellenic Society of Biochemistry and Molecular Biology. November 28-30, 2014, Thessaloniki, Greece.
 30. Amanatiadou E.P., Karavasili C., **Vizirianakis I.S.**, Fatouros D.G. (2014). Development of spray-dried microparticles containing ropinirole hydrochloride: Physicochemical

- characterization and cytocompatibility assessment. 65th Congress of the Hellenic Society of Biochemistry and Molecular Biology. November 28-30, 2014, Thessaloniki, Greece.
31. Amanatiadou E.P., **Vizirianakis I.S.** (2014). In vitro binding of transcription factors GATA-1 and PU1 to the mouse RPS5 proximal promoter region. 65th Congress of the Hellenic Society of Biochemistry and Molecular Biology. November 28-30, 2014, Thessaloniki, Greece.
 32. Amanatiadou E.P., Karavasili C., **Vizirianakis I.S.**, Fatouros D.G. (2014). Development of spray-dried microparticles containing ropinirole hydrochloride: Physicochemical characterization and cytocompatibility assessment. 65th Congress of the Hellenic Society of Biochemistry and Molecular Biology. November 28-30, 2014, Thessaloniki, Greece.
 33. Cox P.A., Nikolakis V., **Vizirianakis I.S.**, Dodd J.L., Slings J. and Fatouros D.G. (2013). Molecular Dynamics Studies of Drug Delivery via Zeolites. 17th International Zeolite Conference (17th IZC), July 7–12, 2013, Moscow, Russia.
 34. Vasili A., Diamantidou S., Rova A., **Vizirianakis I.S.**, Markopoulou A., Kountourellis I., (2013). Spectrometric determination of the pharmaceutical substances hydrochlorothiazide, atenolol, chlorthalidone and their complex mixtures with the application of the First Derivative and the Spectral Ratios Derivation technique. Poster presentation. 16th Pan-Hellenic Pharmaceutical Congress, May 31-June 3, 2013, Athens.
 35. Theodoropoulos D., Rova A., Smith J.R., Barbu E., Calabrese G., **Vizirianakis I.S.**, Tsibouklis J., Fatouros D.G. (2013). Towards boron neutron capture therapy: the formulation and preliminary *in vitro* evaluation of liposomal vehicles for the delivery of the dequalinium salt of bis-*nido*-carborane. Poster presentation. 16th Pan-Hellenic Pharmaceutical Congress, May 31-June 3, 2013, Athens.
 36. Spanakis M., **Vizirianakis I.S.**, Niopas I. Application of the Simcyp® simulation in the pharmacokinetic drug-herb interaction study of losartan with *Rhodiola rosea*. Presentation in the 5th BBBB International Meeting, September 26-28, 2013, Athens, Greece.
 37. Rova A., Amanatiadou E.P., Calabrese G., Tsibouklis J., Fatouros D.G., **Vizirianakis I.S.** (2013) Pharmacological evaluation of new carborane compounds for boron neutron capture therapy of cancer. Poster presentation. In: "Chemical Approaches to Targeting Drug Resistance in Cancer Stem Cells", COST Action CM1106 - 2nd Working Group Meeting, September 19-20, 2013, Warsaw, Poland. (**2nd Best Poster Award**).
 38. Basgiouraki A., Karagkiozaki V., Fatouros D.G., Karagiannidis P.G., Gioti M., **Vizirianakis I.S.** and Logothetidis S. (2012). Development of novel nanomaterials for implants. Poster presentation – Nanomedicine session. "8th International Conference on Nanosciences and Nanotechnologies", July 3-7, 2012, Thessaloniki, Greece.
 39. Spanakis M., **Vizirianakis I.S.**, Mironidou-Tzouveleki M. and Niopas I. (2010). In vitro inhibition of CYP3A4 and CYP2D6 activity by the horse chestnut constituents' aescin and aesculetin. Front. Pharmacol. Conference Abstract: 8th Southeast European Congress on Xenobiotic Metabolism and Toxicity - XEMET 2010. doi: 10.3389/conf.fphar.2010.60.00199.
 40. Spanakis M., **Vizirianakis I.S.** and Niopas I. (2010). Modulation of P- glycoprotein mediated drug transport in Caco-2 cells by Aloe Vera phytotherapeutic products: A methodology to evaluate drug-herb interactions in clinical practice. 6th Panhellenic Congress of Pharmacology, June 4-6, 2010, Heraklion; Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 24: 211-213.
 41. Andreadis D., Kyrodinou M., Barbatis C., Amanatiadou E., Drougou A., Pouloupoulos A., Tsopanomichalou M., Kalekou-Greca H., Epivatianos A. and **Vizirianakis I.S.** (2010). Differential desmogleins-2/3 and gamma-catenin expression in oral leukoplakia/squamous-cell carcinoma. International Association for Dental Research (IADR) meeting, July 14-17, 2009, Barcelona, Spain.
 42. Matragkou C, Papachristou H, Karetsou Z, Papadopoulos G, Papamarcaki T, **Vizirianakis IS**, Tsiftoglou AS, Choli-Papadopoulou T. (2009). On the Intracellular Trafficking of Mouse S5 Ribosomal Protein from Cytoplasm to Nucleoli. 60th Meeting of Hellenic Society of Biochemistry and Molecular Biology, November 20-22, 2009, Athens. Books of Abstracts vol. 55, p. 40.
 43. Chatzopoulou M., Bonovolias I., Polyxeni A., Nicolaou I., **Vizirianakis I.S.**, Demopoulos V. and Tsiftoglou A.S. (2009). In search of new potent inducers of cell differentiation for

- leukemia therapy. Joint Meeting on Medicinal Chemistry, June 24-27, Budapest, Hungary. Book of Abstracts p. 92.
44. Tezias S.S., Tsiftoglou A.S. and **Vizirianakis** I.S. (2008). Cloning and characterization of discrete non-poly(A) RNA transcripts derived from silent 3'- end flanking β major globin gene DNA sequences induced upon blockade of MEL cell differentiation by DNA/RNA methylation inhibitors. 33rd FEBS Congress, June 28-July 3, 2008, Athens; FEBS J. 275(S1): 132.
 45. Papachristou E.T. and **Vizirianakis** I.S. (2008). RNAi-mediated silencing of ribosomal protein S5 gene expression blocks the initiation of MEL cell erythroid differentiation in vitro. 33rd FEBS Congress, June 28-July 3, 2008, Athens; FEBS J. 275(S1): 227.
 46. **Vizirianakis** I.S. (2007). (Invited). The advent of pharmacogenomics and the new era in drug delivery and pharmacovigilance. 13th Panhellenic Pharmaceutical Congress, May 12-14, 2007, Athens. Eur. J. Drug Metab. Pharmacokin. 32:77.
 47. Matragkou C., **Vizirianakis** I.S., Papamarcaki T., Karetsoy Z., Tsiftoglou, A.S., and Choli-Papadopoulou, T. (2007). On the possible involvement of mouse rpS5 phosphorylation in ribosomal biogenesis and cellular differentiation. Amino Acids 33(3), pp. XLIX-L.
 48. Matragkou C., Papachristou E.T., Karetsoy Z., Papamarcaki T., Tsiftoglou A.S., **Vizirianakis** I.S. and Choli-Papadopoulou T. (2006). The NH₂-terminal 1-37 region of ribosomal protein S5 from mouse regulates its intracellular trafficking. 58th Panhellenic Congress of Hellenic Society of Biochemistry and Molecular Biology, November 9-11, 2006, Patras.
 49. Papachristou E.T., Matragkou C., Triviai I.N., Tezias S.S., Tsiftoglou A.S., Choli-Papadopoulou T. and **Vizirianakis** I.S. (2006). The potential involvement of ribosomal protein S5 in the initiation of MEL erythroid cell differentiation and apoptosis. Proceedings of the 4th Panhellenic Congress of Pharmacology, May 19- 20, 2006, Patras. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 20: 276-278.
 50. Tezias S.S., Tsiftoglou A.S. and **Vizirianakis** I.S. (2006). The potential role of β major globin gene 3'-flanking sequences in inhibition of MEL erythroid differentiation by hypomethylating agents. Proceedings of the 4th Panhellenic Congress of Pharmacology, May 19-20, 2006, Patras. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 20: 114-116.
 51. Triviai, I.N., Masiou, S.D., Markala, D.G., Pappas, I.S., **Vizirianakis**, I.S. and Tsiftoglou A.S. (2005). Evidence for induction of apoptosis in differentiating murine erythroleukemia (MEL) cells: Implications in leukemia therapy. European Cell Death Organization Meeting, October 1-4, 2005, Budapest.
 52. Pappas I.S., Lambris J., **Vizirianakis**, I.S., Winter M.S. and Tsiftoglou A.S. (2004). Detection of inducer-binding protein(s) in murine erythroleukemia and neuroectodermal cells. Presentation at the 56th meeting of the HSBMB, November 25-27, Larissa, Greece. Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter), vol. 51, Larissa 2004.
 53. Matragkou, C., **Vizirianakis**, I.S., Papamarcaki, T., Karetsoy, Z., Tsiftoglou, A. S. and Choli-Papadopoulou, T. (2004). On the possible involvement of mouse rpS5 phosphorylation in ribosomal biogenesis and cellular differentiation. 15th Meeting "Methods in Protein Structure Analysis" August 29 to September 2, 2004, Seattle, Washington, U.S.A.
 54. Tsiftoglou A.S., Gougoumas D., Masiou S. and **Vizirianakis** I.S. (2004). Exploring the role of apoptosis in erythroid cell differentiation with the use of murine erythroleukemia (MEL) cell system. Keystone Symposia: "HEMATOPOIESIS", Tahoe City, California, March 12-17, 2004; Abstract Book p. 68.
 55. Gougoumas D., **Vizirianakis** I.S., Sklaviadis T. and Tsiftoglou A.S. (2004). Production of prion protein (PrP^C) in transfected murine erythroleukemia (MEL) and neuronal N2a cells overexpressing PrP RNA transcripts. Proceedings of the 3rd Panhellenic Conference in Pharmacology. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 18: 43-44.
 56. **Vizirianakis** I.S., Tezias S.S. and Tsiftoglou A.S. (2004). DNA/RNA methylation inhibitors block murine erythroleukemia cell differentiation and promote accumulation of discrete small RNA species: Implications in activation of silent DNA sequences by pharmacological agents. Proceedings of the 3rd Panhellenic Conference in Pharmacology. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition), 18: 40-42.

57. Matragou, C., Choli-Papadopoulou, T., and **Vizirianakis**, I.S. (2003). Transfection of murine erythroleukemia cells with full length ribosomal protein S5 cDNA altered the onset of erythroid differentiation. *Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter)*, 50: 406-410.
58. Matragou, C., **Vizirianakis**, I.S., Tsiftoglou, A.S., Andreou-Koudou, S. and Choli-Papadopoulou, T. (2002). Expression and structural analysis of S5 mouse ribosomal protein. "14th Meeting Methods of Protein Structure Analysis", The biennial meeting of the International Association for Protein Structure Analysis and Proteomics, Valencia, Spain, September 8th- 12th, 2002.
59. **Vizirianakis** I.S. and Tsiftoglou A.S. (2002). Impact of Pharmacogenomics and other drug development technologies on modern Pharmacology and Therapeutics. *Proceedings of the 2nd Panhellenic Conference in Pharmacology. Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition)*, 16: 36-37.
60. Tsiftoglou A.S., Pappas, I.S., **Vizirianakis**, I.S., Sidiropoulou A. and Papadopoulou L.C. (2001). Mechanisms of differentiation and differentiation dependent-apoptosis (DDA) in leukemic cells. *Oncol. Res.*, 12: 273.
61. **Vizirianakis**, I.S. and Tsiftoglou, A.S. (2000). Detection of unique structural elements within the 3'-flanking sequences of mouse β major globin gene: implications in differentiation of mouse erythroleukemia (MEL) cells. *Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter)*, 47: 52-55.
62. **Vizirianakis**, I.S., Pappas, I.S. and Tsiftoglou A.S. (2000). Cloning and expression of two cDNAs encoding the S5 and L35a ribosomal proteins in differentiating and apoptotic murine erythroleukemia (MEL) cells. *Proc. Eur. Assoc. Cancer Res. 16th meeting, 30 May-3 June 2000, Halkidiki, Hellas*, p. 63.
63. **Vizirianakis**, I.S., Chen Y-Q., Katak S., Tsiftoglou A.S. and Kramer R.H. (2000). Alterations in adhesion, morphology, and growth of MCF-7 breast carcinoma cells transfected with a dominant-negative E-cadherin mutant. *Proc. Amer. Assoc. Cancer Res.*, 41: 472.
64. **Vizirianakis**, I.S., Tsiftoglou A.S. and Kramer R.H. (1999). The cell adhesion molecules integrins and cadherins as molecular targets for anticancer therapeutics development. *Proceedings of the 1st Panhellenic Conference in Pharmacology, Published in Rev. Clin. Pharmacol. Pharmacokin. (Greek Journal-International Edition)*, 13: 92-93.
65. **Vizirianakis**, I.S., Tsiftoglou A.S. and Kramer R.H. (1999). Isolation and characterization of full-length human integrin alpha-7 cDNA. *Proc. Hellenic Soc. Biochem. Mol. Biol. (Newsletter)*, 46: 185-189.
66. Gougoumas D., **Vizirianakis** I.S., Sklaviadis T. and Tsiftoglou A.S. (1999). Transcriptional activation of prion protein (PrP) gene in growth arrested and terminally differentiated cells by chemical inducers. In the meeting "Drug Discovery '99", 22-24 September, Sandwich, Kent, U.K.
67. **Vizirianakis** I.S., Chen Y-Q. and Kramer R.H. (1998). Transfection of epithelial cells with E-cadherin dominant-negative construct disrupts cell-cell adhesion. *Mol. Biol. Cell*, 9(suppl.): 49a.
68. **Vizirianakis** I.S. and Tsiftoglou A.S. (1997). Detection of RNA transcripts hybridized to the flanking sequences of β major globin gene in murine erythroleukemia cells exposed to hypomethylating agents. *Anticancer Res.*, 17(5C): 3965.
69. **Vizirianakis** I.S., Christou E-I. and Tsiftoglou A.S. (1996). Inhibition of RNA methylation leads to selective degradation of β major globin mRNA in MEL cells. 24th FEBS meeting, July 7-12, Barcelona Spain.
70. **Vizirianakis** I.S., Pappas I.S. and Tsiftoglou A.S., (1995). Isolation and characterization of cDNAs of developmentally regulated genes from murine erythroleukemia (MEL) cells. "NATO Advanced Study Institute: Regulation of cell growth, differentiation and genetics in cancer", September 1-12, Halkidiki, Greece.
71. **Vizirianakis** I.S., Pappas I.S. and Tsiftoglou A.S., (1995). Isolation and sequencing of a cDNA of a developmentally regulated gene encoding a S5-like rat ribosomal protein from murine erythroleukemia (MEL) cells. *Proc. Hellenic Biochem. Biophys. Soc., (Newsletter)*, 38: 56-57.

72. **Vizirianakis** I.S. and Tsiftoglou A.S., (1993). Induction of specific events of murine erythroleukemia cell differentiation depends on RNA methylation. *Mol. Cell. Dif.*, 1(4): 385.
73. Tsiftoglou A.S., Christou I.E. and **Vizirianakis** I.S., (1992). Developmental changes in methylation of polyA+ RNA may regulate its stability post-transcriptionally in murine erythroleukemia (MEL) cells. *Proc. Amer. Assoc. Cancer Res.*, 33: 48.
74. **Vizirianakis** I.S., Niopas I., Marquez V.E. and Tsiftoglou A.S. (1992). Several inhibitors of DMSO-induced differentiation suppress methylation of RNA in murine erythroleukemia cells. *Ann. Oncol.*, 3 (Suppl 1): 182.
75. **Vizirianakis** I.S., Niopas I. and Tsiftoglou A.S. (1991). Alterations in methylation of ribosomal RNAs during differentiation of murine erythroleukemia (MEL) cells. *Proc. Hellenic Biochem. Biophys. Soc.*, (Newsletter), 33: 21-23.
76. **Vizirianakis** I.S., Marcopoulou C., Kountourellis J.E., Papadopoulou L.C. and Tsiftoglou A.S., (1990). RNA methylation as a key-regulatory process in growth and differentiation of murine erythroleukemia (MEL) cells: inhibition by N6- methyladenosine (N6meAdo). *Proc. Amer. Assoc. Cancer Res.*, 31: 35.
77. **Vizirianakis** I.S., Tsiftoglou A.S. (1987). Implications of N6- methyladenosine blockade of commitment in the molecular analysis of chemically- induced differentiation of murine erythroleukemia (MEL) cells. *Proc. Hellenic Biochem. Biophys. Soc.*, (Newsletter), 26: 34-36.
78. Tsiftoglou A.S., **Vizirianakis** I.S. and Wong W., (1987). Analysis of the mechanism(s) of N6-methyladenosine-induced inhibition of commitment of murine erythroleukemia (MEL) cells to terminal maturation. 18th FEBS meeting, Ljubljana, Yugoslavia, Abstracts p. 274.

In Greek

79. Χατζοπούλου Μ., Νικολάου Ι., Μπονοβόλιας Ι., **Βιζιριανάκης** Ι.Σ. και Τσιφτσόγλου Α. (2008). Σύνθεση του 5-(1Η-πυρρολ-1-υλο)-1Η-τετραζολίου και παραγώγων αυτού με αντιλευχαιμική δράση. 13ο Πανελλήνιο Συμπόσιο Φαρμακοχημείας, 14-15 Μαρτίου 2008, Αθήνα.
80. **Βιζιριανάκης**, Ι.Σ. (2003). Φαρμακογονιδιωματική: Η γενετική βάση της διαφορικής φαρμακολογικής απόκρισης στα φάρμακα και της εξατομίκευσης της φαρμακευτικής αγωγής στην κλινική πράξη. 11ο Πανελλήνιο Φαρμακευτικό Συνέδριο, 29-31 Μαρτίου, 2003. Αθήνα.
81. **Βιζιριανάκης**, Ι.Σ. και Τσιφτσόγλου, Α.Σ. (2001). Οι κατχερίνες και ιντεγκρίνες ως στόχοι για την ανάπτυξη νέων φαρμάκων αλλά και συστημάτων ενδοκυτταρικής μεταφοράς φαρμακευτικών ουσιών. 10ο Πανελλήνιο / 1ο Διεθνές Φαρμακευτικό Συνέδριο, 27-30 Απριλίου, 2001, Αθήνα. CD-ROM τόμου πρακτικών συνεδρίου, Εργασία Αρ. 2016. Φαρμακευτική 14(II):65-66, 2001.
82. **Βιζιριανάκης**, Ι.Σ. (2001). Σύγχρονη Φαρμακευτική Εκπαίδευση και Νέες Τεχνολογικές και Επιστημονικές Εξελίξεις στον Τομέα Έρευνας και Ανάπτυξης Φαρμάκων. 10ο Πανελλήνιο / 1ο Διεθνές Φαρμακευτικό Συνέδριο, 27-30 Απριλίου, Αθήνα, 2001. CD-ROM τόμου πρακτικών συνεδρίου, Εργασία Αρ. 1959.
83. Κριτής, Α.Α., Παππάς, Α.Σ., Μπορσαλη-Τσιφτσόγλου, Θ., **Βιζιριανάκης**, Ι.Σ., Δρετάκη Π. και Τσιφτσόγλου, Α.Σ. (1999). Βιοτεχνολογική παραγωγή ετερόλογων πολυπεπτιδίων από γενετικά τροποποιημένους μικροοργανισμούς (GMOs). Πόστερ που αναρτήθηκε στην Έκθεση Βιοτεχνολογίας με θέμα "Focus on genes" που υλοποιήθηκε σε συνεργασία του Deutsches Hygiene Museum Dresden και του Τεχνικού Μουσείου Θεσσαλονίκης και πραγματοποιήθηκε στη Θεσσαλονίκη 1-17 Οκτωβρίου, 1999.
84. **Βιζιριανάκης** Ι.Σ., Τσιφτσόγλου Α.Σ. και Σκλαβιάδης Θ. (1993). Νεότερες εξελίξεις στην έρευνα νευροεκφυλιστικών ασθενειών που οφείλονται στη δράση αργών ιών. 9η Πανελλήνια συνάντηση για τις Νευροεπιστήμες, 25-28 Νοεμβρίου, Θεσσαλονίκη, Πρακτικά σελ. 15.
85. **Βιζιριανάκης** Ι.Σ. και Τσιφτσόγλου Α.Σ. (1990). Οι αντιδράσεις μεθύλισης των νουκλεϊνικών οξέων ως στόχος για την ανάπτυξη χημειοθεραπευτικών. Πρακτικά 5ου Πανελληνίου Φαρμακευτικού Συνεδρίου, Αθήνα, σελ. 250-255.

A-5. Research articles in Greek Journals and Specific Editions

1. Μυστριδής Γ., **Βιζιριανάκης** Ι.Σ. (2016). Η βασισμένη στη φυσιολογία φαρμακοκινητική προσομοίωση ως εργαλείο στην εξατομίκευση της συνταγογράφησης των αντιβιοτικών στην κλινική πράξη. *ΑΡΙΣΤΟΤΕΛΗΣ*, 33: 8-22.

2. **Βιζιριανάκης** Ι.Σ. (2014). Εξατομικευμένη Ιατρική Πρακτική & Φαρμακευτική Αγωγή. Free article in the web site "Quality in Health". URL: <http://www.qualityinhealth.gr/index.php/arhra/katigories-arthrwn/item/116-eksatomikevmeni-iatriki-praktiki-farmakeftiki-agogi-ioannis-s-vizirianakis>
3. **Βιζιριανάκης**, Ι.Σ. (2008). Φαρμακογονιδιωματική: Καινοτομία στη φαρμακευτική αγωγή. Φαρμακευτικά και... Επίκαιρα, Τεύχος 5(Ιούλιος-Αύγουστος): 8-12.
4. **Βιζιριανάκης**, Ι.Σ. (2007). Φαρμακογονιδιωματική και εξατομίκευση της φαρμακευτικής αγωγής. Στο βιβλίο: Κοινωνία & Υγεία VI, «Σειρά Επιστήμης Κοινωνία», σελ. 99-111, Εθνικό Ίδρυμα Ερευνών, Αθήνα.
5. **Βιζιριανάκης**, Ι.Σ. (2006). Κλινική σημασία των αλληλεπιδράσεων φαρμάκων με τρόφιμα: Το παράδειγμα του χυμού grapefruit. ΑΡΙΣΤΟΤΕΛΗΣ, 19: 39- 41.
6. **Βιζιριανάκης**, Ι.Σ. (2005). Διοξίνες, το φάρμακο της ζωής μας... Ιατρικά, Τεύχος 150, σελ. 14-21. (ΕΝΘΕΤΟ-Εφημερίδα «Ελευθεροτυπία», 25 Ιανουαρίου 2005).
7. **Βιζιριανάκης**, Ι.Σ. (2005). Αποτελεσματικότητα και ασφάλεια στη φαρμακευτική αγωγή: Ο ρόλος της φαρμακογονιδιωματικής. ΑΡΙΣΤΟΤΕΛΗΣ, 18: 15- 19.
8. **Βιζιριανάκης**, Ι.Σ. (2003). Η φαρμακευτική εκπαίδευση ενώπιον των εξελίξεων στις γονιδιακές τεχνολογίες για την ανάπτυξη φαρμάκων και εξατομικευμένης παροχής ιατρικών υπηρεσιών. Φαρμακευτικό Δελτίο, Τεύχος 611(Μαΐου): 332-339. (Πρόκειται για μετάφραση του άρθρου A10 που δημοσιεύτηκε στο Eur. J. Pharm. Sci. μετά από έγγραφη άδεια του εκδότη).
9. **Βιζιριανάκης**, Ι.Σ. (2002). Η φαρμακευτική εκπαίδευση ενώπιον των εξελίξεων στις γονιδιακές τεχνολογίες για την ανάπτυξη φαρμάκων και εξατομικευμένης παροχής ιατρικών υπηρεσιών. Φαρμακευτική, 15(IV): 127-136. (Πρόκειται για μετάφραση του άρθρου A10 που δημοσιεύτηκε στο Eur. J. Pharm. Sci. μετά από έγγραφη άδεια του εκδότη).
10. **Βιζιριανάκης**, Ι.Σ. (2001). Σύγχρονη φαρμακευτική έρευνα και εκπαίδευση: Από τα γονίδια στην ανάπτυξη νέων θεραπευτικών (B' Μέρος). Φαρμακευτικός Κόσμος, Τεύχος 73 (Οκτώβριος-Νοέμβριος), σελ. 58-62.
11. **Βιζιριανάκης**, Ι.Σ. (2001). Σύγχρονη φαρμακευτική έρευνα και εκπαίδευση: Από τα γονίδια στην ανάπτυξη νέων θεραπευτικών (A' Μέρος). Φαρμακευτικός Κόσμος, Τεύχος 72 (Αύγουστος-Σεπτέμβριος), σελ. 66-74.
12. **Βιζιριανάκης**, Ι.Σ. (2000). Η χρήση του Διαδικτύου ως πηγή αναζήτησης επιστημονικών πληροφοριών για τα φάρμακα και ανάπτυξης επιμορφωτικών προγραμμάτων για τους φαρμακοποιούς. Φαρμακευτικό Δελτίο, 580: 31-32.
13. **Βιζιριανάκης**, Ι.Σ. (2000). Προσαρμογή της Φαρμακευτικής εκπαίδευσης στις νέες κατευθύνσεις έρευνας και ανάπτυξης νέων θεραπευτικών. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν., 18: 101-120.
14. **Βιζιριανάκης**, Ι.Σ. (2000). Φαρμακευτική βιοτεχνολογία και ανάπτυξη νέων φαρμάκων στη σύγχρονη Φαρμακολογία. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν., 18: 61-72.
15. Τσιφτσόγλου, Α.Σ., **Βιζιριανάκης**, Ι.Σ., Παππάς, Ι.Σ. και Παπαδοπούλου Λ. (2000). Μηχανισμοί διαφοροποίησης και απόπτωσης νεοπλασματικών κυττάρων. Πρακτικά 7ου Μετεκπαιδευτικού Συνεδρίου Κλινικής Ογκολογίας: "Εξελίξεις στην Ογκολογία του 1999", (Εκδότης Β.Α. Γεωργούλιας), σελ. 449-453, Παγκρήτια Ένωση Βιοϊατρικής Έρευνας, Ηράκλειο Κρήτης.
16. **Βιζιριανάκης**, Ι.Σ., Τσιφτσόγλου Α.Σ. και Kramer R.H. (1999). Οι πρωτεΐνες συγκόλλησης ιντεγκρίνες και κατχερίνες ως στόχος για την ανάπτυξη νέων αντινεοπλασματικών χημειοθεραπευτικών. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν., 16: 149-160.
17. **Βιζιριανάκης**, Ι.Σ., Τσιφτσόγλου Α.Σ. (1995). Ο ρόλος της σταθερότητας μορίων του αγγελιαφόρου RNA (mRNA) στον έλεγχο της γενετικής έκφρασης στα ευκαρυωτικά κύτταρα και στην ανάπτυξη θεραπευτικών ουσιών. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν., 13: 7-32.
18. **Βιζιριανάκης**, Ι.Σ., Τσιφτσόγλου Α.Σ. (1992). Ο βιολογικός ρόλος της μεθυλίωσης του DNA στη μεταγραφή των γονιδίων και στην ανάπτυξη νέων θεραπευτικών ουσιών. Επιθ. Κλιν. Φαρμακολ. Φαρμακοκιν., 10: 43-57.